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 Zusammenfassung I 
 
Zusammenfassung 
 
Herz-Kreislauf-Erkrankungen sind weltweit die häufigste Todesursache. In den letzten Jahren 
haben besonders zellbasierte Therapien mit dem Ziel Herztransplantationen zu vermeiden 
breite Aufmerksamkeit erregt. Im Besonderen aus Knochenmark isolierte humane 
mesenchymale Stammzellen (hMSZ) konnten durch ihr großes therapeutisches Potential in 
der regenerativen Medizin überzeugen. Die meisten klinischen und präklinischen Studien 
wurden jedoch mit expandierten hMSZ durchgeführt, die das Risiko von Verunreinigungen 
und des Verlusts der Stammzelleigenschaften bergen. Daher sind frisch isolierte Zellen trotz 
niedrigerer Erträge für klinische Anwendungen zu bevorzugen. Es ist bewiesen, dass das 
Regenerationspotential von hMSZ durch genetische Modifikationen mittels mikroRNAs 
(miRs) verbessert werden kann. Darüber hinaus sind DNA-freie Transfektionsmethoden 
weniger riskant für die klinische Anwendung im Menschen. Dennoch sind bis heute keine 
sicheren und klinisch relevanten miR Transfermethoden entwickelt worden. In 
vorangegangenen Studien unserer Arbeitsgruppe gelang es, einen magnetischen nicht-viralen 
Vektor, bestehend aus dem kationischen Polymer Polyethylenimin (PEI), das über Biotin-
Streptavidin Binding an magnetische Eisenoxidnanopartikel (MNP) gebunden ist, zu 
entwickeln und damit DNA effizient in expandierte hMSZ einzubringen. Außerdem bieten 
MNP-haltige Komplexe zusätzliche Vorteile: sie ermöglichen eine verbesserte Selektivität 
und Sicherheit der Transfektionsvektoren und geringere Nebenwirkungen in vivo. Daher war 
es das Ziel, diesen Ansatz für den effizienten Transfer von miRs in frisch isolierte hMSZ zu 
übertragen. Zusätzlich sollte überprüft werden, ob die magnetisch veränderten Stammzellen 
mit Hilfe eines externen Magnetfeldes in vitro zielgerichtet gelenkt werden können. Initial 
wurde eine optimale Zusammensetzung des Transfektionskomplexes entwickelt zur 
effizienten Modifikation von expandierten hMSZ. Neben höchsten miR Transfektionsraten 
zeigte der optimierte magnetische Vektor eine bessere und länger andauernde Wirksamkeit im 
Vergleich zur PEI-basierten Transfektion. Aufbauend auf den gewonnen Erkenntnissen 
gelang es, mit dem magnetischen, nicht-viralen Vektor miR effizient in frisch isolierte hMSZs 
(~ 70% Aufnahmeeffizienz) einzubringen. Im Vergleich zu kommerziell erhältlichen, 
magnetischen Transfektionsreagenzien, die für den effizienten DNA-Transfer getestet sind, 
konnte der neuentwickelte magnetische Vektor gleiche Aufnahmeeffizienzen erzielen. Es 
wurde gezeigt, dass alle untersuchten magnetischen Transfektionskomplexe für einen 
potenziellen Einsatz zur Modulation von Stammzellen mit miRs geeignet sind. Zusätzlich 
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wurde der Nachweis erbracht, dass sowohl frisch isolierte als auch expandierte hMSZ nach 
Transfektion mit den entsprechenden miR/PEI/MNP Komplexen spezifisch durch ein von 
außen angelegtes Magnetfeld gelenkt werden konnten. Dies soll ein verbessertes Anwachsen 
des Stammzelltransplantates in vivo unterstützen und damit das Regenerationspotenzial der 
Stammzellen erhöhen. Im Rahmen dieser Dissertation konnte somit ein magnetischer, nicht-
viraler Vektor entwickelt werden, der nachweislich miR effizient in frisch isolierte 
Stammzellen einschleust mit dem Ziel die Stammzelleigenschaften gezielt zu steuern. 
Zusätzlich besteht die Möglichkeit die modifizierten Stammzellen durch ein externes 
Magnetfeld präzise in vivo zu lenken. Damit können die Ergebnisse als Grundlage für die 
Entwicklung innovativer Strategien zur Regeneration des geschädigten Herzens dienen. 
 
Schlagwörter: mesenchymale Stammzellen, CD105; nicht-viraler Gentransfer, mikroRNA; 
magnetische Nanopartikel, Polyethylenimin; Magnetofektion 
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Summary 
 
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide. 
During the last years, cell-based therapies gained huge attention for regeneration of the 
injured heart aiming to avoid heart transplantation. In particular, bone marrow derived human 
mesenchymal stem cells (hMSCs) have been shown great therapeutic potential in regenerative 
medicine. However, most trials were using culture expanded hMSCs that bear the risk of 
contaminations and loss of their stem cell character. Thus, freshly isolated cells might be 
preferable for clinical applications. In recent years, it was shown that the regenerative 
properties of hMSCs can be enhanced by genetic modifications using microRNAs (miRs). 
Moreover, DNA-free transfection methods bear less safety risks. However, safe and effective 
miR delivery methods suitable for clinical applications have not been developed, yet. 
Previously, our group succeeded to efficiently deliver DNA into expanded hMSCs using a 
magnetic non-viral vector consisting of cationic polymer polyethylenimine (PEI) bound to 
iron oxide magnetic nanoparticles (MNPs). Moreover, MNP-containing complexes enable 
improved selectivity and safety of delivery and reduced side effects in vivo. Thus, the aim of 
this thesis was to adopt this approach for efficient miR delivery in freshly isolated hMSCs 
using miR/PEI/MNP complexes and to show proof-of-concept for magnetic targeting of 
transfected cells in vitro. Initially, the optimal complex formulation was determined for 
efficient modification of expanded hMSCs. Moreover, we assessed transfection efficiencies of 
MNP-based complexes and found a better long term performance compared to polyplex 
transfection, which might be beneficial considering clinical use. Afterwards, we succeeded to 
transfer our magnetic non-viral approach for efficient miR delivery to freshly isolated hMSCs 
(~ 70% uptake efficiency). Additionally, MNP-based transfection was compared to magnetic 
transfection reagents commonly used for DNA delivery. Interestingly, our MNP-containing 
complexes yielded similar uptake rates. Hence, all investigated magnetic transfection reagents 
have the potency to deliver miRs in hMSCs. Moreover, it was demonstrated that freshly 
isolated and expanded hMSCs could be specifically guided by an externally applied magnetic 
field after transfection with the corresponding miR/PEI/MNP complexes contributing to 
enhanced cell retention and engraftment of transplanted cells in vivo. Conclusively, in this 
thesis a magnetic non-viral carrier for efficient miR delivery in freshly isolated stem cells was 
developed allowing specific control of stem cell properties as well as precise magnetic 
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targeting of transfected cells in vivo. Therefore, we expect that our approach will serve as a 
basis for innovative strategies to regenerate the injured heart. 
 
Keywords: mesenchymal stem cells; CD105; non-viral carrier; microRNA; magnetic 
nanoparticles; polyethylenimine; magnetofection 
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1 Introduction 
 
1.1 Prospective Stem Cell Resources for Cardiac Regeneration 
 
Cardiovascular diseases (CVDs) are the leading cause of death worldwide according to the 
statistics of the World Health Organization (WHO). In 2008, approximately 17.3 million 
deaths were caused by CVDs. Forecasts predict a further global increase of cardiovascular 
deaths to 23.3 million in 2030  [1]. Among them, ischemic heart diseases are the most 
common causes of death (~ 7.3 million)  [2]. Ischemic heart failures are caused by a sudden 
occlusion of the coronary arteries following a limited myocardial perfusion. Consequently, 
cardiomyocytes die due to oxygen deprivation which initiates, for example (e.g.) the 
formation of a non-contractile scar, ventricular wall thinning up to the formation of sustained 
heart failure and under certain circumstances death  [3]. So far, preventive strategies, drug 
therapies and surgical or interventional reperfusion methods are available to treat 
cardiovascular diseases by ensuring coronary perfusion, prevention of cardiac arrhythmias 
and improving the efficiency of the remaining cardiac function  [4, 5]. After the establishment 
of a chronic heart failure in the end-stage, heart transplantation remains the only therapeutic 
option  [6]. However, due to the restricted access of donor hearts and risks in the subsequent 
immunosuppressive therapy only a limited amount of patients can be treated. According to the 
statistics from Eurotransplant, about 590 hearts were transplanted in Europe in 2013. 
However, more than twice as many donor organs would be required  [7]. 
Therefore, targeted causal and curative therapies for the regeneration of the heart or the 
replacement of damaged cardiomyocytes have to be developed. For these reasons, the 
attention has turned to cell-based therapies. Stem cell transplantation has emerged as a 
potential therapeutic strategy for repopulating injured heart tissue. For myocardial 
regeneration therapies several stem cell sources are under investigation: human embryonic 
stem cells (hESCs), induced pluripotent stem cells (iPSCs) and human adult stem cells. 
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1.1.1 Human Embryonic Stem Cells 
 
In 1998, hESCs have been first derived from the inner cell mass of the blastocyst of the 
developing embryo. Due to their pluripotency, they have the potential to differentiate into cell 
types of all three germ layers (endoderm, ectoderm and mesoderm)  [8]. In 2001, researchers 
for the first time succeeded in the differentiation of human embryonic stem cells into early 
stage cardiomyocytes. These cells showed spontaneous contractions and expressed both early 
cardiac transcription factors (e.g. GATA4, Nkx2.5 and MEF) and specific structural proteins 
of the heart muscle  [9]. Therefore, with respect to their pluripotency and their high 
proliferation rate as well as the functionality of differentiated cells, hESCs show great 
potential for cardiac regeneration  [10]. On the other hand, hESCs bear the risk of teratoma 
formation, the development of arrhythmias and the problem of immunological rejection of 
donor cells. In addition, previously it has been shown, that less than 5% of hESCs were able 
to differentiate into cardiomyocytes  [11, 12]. Moreover, the use and research of hESCs are 
ethically problematic. Due to the ethical and legal restrictions in Germany (embryo protection 
law, ESchG, see BGBl. I 1990/2746), the realization of new regenerative therapies based on 
hESCs does not seem to be feasible in the near future. 
 
1.1.2 Induced Pluripotent Stem Cells 
 
Based on the existing limitations of hESCs, researchers have been looking for a way to obtain 
pluripotent cells which can circumvent the ethical and political limitations. In 2012, the Nobel 
Prize in Physiology or Medicine was awarded to Dr. Yamanaka for his discovery of 
reprogramming mature differentiated cells into a pluripotent stem cell state. Initially, it was 
shown that mouse embryonic fibroblasts could be reprogrammed into iPSCs by introducing 
four transcription factors (Oct3/4, Sox2, c-Myc and Klf4)  [13]. One year later, Yamanaka’s 
group succeeded to convert adult human somatic cells into iPSCs using the same factor 
combination  [14]. In the fast growing field of reprogramming, recently the world’s first 
clinical trial involving iPSCs was approved by the Japanese Ministry of Health, Labor and 
Welfare. Thereby, an iPSC derived retinal pigment epithelium was transplanted into patients 
suffering from age related macular degeneration  [15]. Moreover, it was shown, that iPSCs 
were able to differentiate into spontaneous beating cardiomyocytes which was proven by the 
expression of specific cardiac markers, morphology, cross-striation as well as calcium 
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transients  [16, 17]. Recently, Kempf et al succeeded to develop a cardiac differentiation 
protocol with clinically applicable yields and purity (~ 85% iPSC derived cardiomyocytes) 
using chemical Wnt  [18]. However, the currently produced iPSC derived cardiomyocytes 
retain in an immature state as indicated by an altered morphology and physiology when 
compared to mature cells (differences summarized in  [19]). Thus, impaired electrical and 
mechanical integration within adult myocardium are still limiting the application of iPSC 
technology for cardiac regeneration at present  [20]. Therefore, despite the great therapeutic 
potential of iPSCs for cardiac regeneration to generate autologous disease-specific pluripotent 
cells, further studies have to be performed before applying them in the clinic. 
 
1.1.3 Human Mesenchymal Stem Cells 
 
Other promising cell sources for cardiac regeneration are human adult stem cells. They are 
multipotent (differentiation into various cell types of one germ layer) and have the potential 
for self-renewing. Moreover, the use of these cells is ethically unproblematic. One of the most 
investigated adult stem cells are human mesenchymal stem cells (hMSCs). In 1968, 
Friedenstein et al first described mesenchymal stem cells (MSCs) as adherent spindle-shaped 
fibroblast-like cells. These cells were located in the bone marrow and were able to 
differentiate  [21]. In order to standardize and characterize MSCs, the International Society 
for Cellular Therapy determined criteria to define MSCs in 2006. In this regard, cells must be 
adherent to plastic under common culture conditions. They have to express specific cell 
surface markers (e.g. cluster of differentiation (CD) 29, CD44, CD73, CD105) and lack the 
expression of CD11b, CD14, CD19, CD34, CD45, CD79α, CD117 and human leukocyte 
antigen (HLA)-DR. Furthermore, MSCs must have the ability to differentiate into adipocytes, 
osteocytes and chondrocytes under certain culture conditions  [22]. 
MSCs have been identified in various tissues, e.g. bone marrow, brain, liver, spleen, lung, 
kidney, skin, muscle, adipose tissue, aorta, vena cava, pancreas, thymus and umbilical cord 
blood  [23, 24, 25, 26]. Yet, the most abundant organ is the bone marrow  [27]. For efficient 
isolation of hMSCs from tissue, different methods can be used. One common technique is the 
isolation using plastic adherence. This is a cheap and easy but also unspecific and time 
consuming process. Furthermore, hMSCs can be obtained via magnetic activated cell sorting 
(MACS). Therefor magnetically labelled antibodies against specific stem cell surface markers 
are used. Previously, it was shown, that CD105 (endoglin) is a suitable surface marker for 
 1 Introduction 4 
 
 
 
efficient purification of hMSCs from bone marrow  [28]. Endoglin, is a homodimeric integral 
membrane protein (180kDa) which acts as an accessory type III receptor (TβR-III) and is able 
to bind different molecules of the transforming growth factor (TGF)-β superfamily (e.g. TGF-
β1, TGF-β3, activin-A, bone morphogenetic protein (BMP)-7 and BMP-2) in combination 
with TβR-I or TβR-II  [29, 30, 31]. Though the specific function of endoglin yet needs to be 
analysed, previous publications claimed that CD105 is involved in angiogenesis and vascular 
remodelling  [32, 33]. After efficient isolation, MSCs can be expanded in vitro to reach the 
desired cell number for autologous applications in vivo  [34]. However, it has been proposed 
that cell expansion might influence their differentiation potential and homing ability  [28, 35]. 
In March 2015, 265 clinical trials are using MSCs for a wide range of indications 
(cardiovascular diseases  [36, 37], bone/ cartilage disorders  [38], diabetes  [39], liver 
diseases  [40], autoimmune disorders  [41] and neuromuscular diseases  [42])  [43]. It was 
shown that MSCs exert their therapeutic effect by numerous mechanisms. They are able to 
migrate to the site of injury guided by a range of growth factors and chemokines like platelet-
derived growth factor, insulin-like growth factor-1 (IGF-1) and C-C chemokine receptor 
(CCR) 2, CCR3, CCR4  [44]. Moreover, they can differentiation into various cell types, e.g. 
cartilage, bone, tendon, ligament, adipose tissue, marrow stroma and connective tissue as well 
as into endothelial cells and smooth muscle cells  [37, 45, 46, 47, 48]. Previously, it was 
shown that a small number of MSCs had the ability to transdifferentiate into a cardiomyocyte-
like phenotype in vitro and in vivo [48, 49]. However, these cells failed to generate functional 
cardiomyocytes indicating that their transdifferentiation potential might not be sufficient for 
cardiac regeneration  [50]. Moreover, MSCs are able to secret a large spectrum of trophic 
factors, e.g. soluble extracellular matrix glycoproteins (collagen type I and II, osteopontin), 
cytokines (TGF-β, interleukin (IL)-10, IL-6) and growth factors (vascular endothelial growth 
factor (VEGF), keratinocyte growth factor, hepatocyte growth factor (HGF)), to activate cell 
regeneration and inhibit inflammation and apoptosis of damaged tissue  [51]. Furthermore, 
they can perform immunomodulatory functions by suppressing T cells, dendritic cell 
maturation and B cell activation, stimulating regulatory T cells via IL-10 as well as inhibiting 
natural killer cells  [52, 53, 54, 55, 56, 57, 58]. Moreover, MSCs can release soluble 
immunosuppressive factors like prostaglandins and various growth factors  [59]. The clinical 
trials showed that MSCs seem to be well tolerated. Most studies reported no adverse 
effects  [60]. Therefore, MSCs are promising cell sources for clinical applications in heart 
surgery. 
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1.2 Modifications of Mesenchymal Stem Cells for Cardiac Regeneration 
 
Despite the great benefits of MSCs, clinical applications of MSC-based therapies are limited 
due to the poor viability of cells after transplantation into the myocardium  [61]. In 2002, 
Toma et al showed that less than 0.5% of transplanted MSCs survived in the intact heart after 
4 days  [49]. To face the problem of low cell survival rates after cell injection, several 
strategies to specifically modify MSCs before transplantation have been investigated. 
 
1.2.1 Pretreatment of Mesenchymal Stem Cells 
 
MSCs can be pretreated with different growth and differentiation factors to facilitate their 
viability and engraftment in cardiac tissue  [62, 63, 64]. Pasha et al showed that 
preconditioning of MSCs using stromal-derived factor 1 (SDF-1) enhanced cell survival, 
angiogenesis and cell homing in the infarcted heart compared to untreated cells by activating 
the Akt signaling pathway  [64]. Moreover, it was shown that incubation of MSCs with TGF-
α improved myocardial recovery by stimulating VEGF production after myocardial 
injury  [65]. Furthermore, MSCs can be treated with pharmaceuticals before transplantation. 
Recently, it was demonstrated that pretreatment of MSCs with atorvastatin (competitive 
inhibitor of the HMG-CoA reductase) facilitated differentiation towards a cardiomyocyte-like 
phenotype and cell survival by activating endothelial nitric oxide synthase (eNOS)  [66, 67]. 
Moreover, estradiol treatment of MSCs before transplantation into the heart improved cardiac 
function and cell viability by enhancing VEGF production  [68]. Furthermore, Liu et al 
demonstrated that incubation of MSCs with lysophosphatidic acid prior transplantation 
enhanced MSC survival in ischemic myocardium  [69]. 
 
1.2.2 Preconditioning of Mesenchymal Stem Cells 
 
Additionally, different methods for preconditioning of MSCs prior to transplantation are 
under investigation. It was shown that preconditioning of MSCs using heat shock had a 
beneficial effect on the proliferation and differentiation potential of MSCs in vitro  [70]. 
Moreover, hypoxic preconditioning of MSCs enhanced cell viability of transplanted cells and 
angiogenesis in the infarcted heart due to increased expression of pro-survival and pro-
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angiogenic factors (e.g. hypoxia-inducible factor-1α (HIF-1α), angiopoietin-1, VEGF, fetal 
liver kinase-1 (Flk-1), erythropoietin, IL-6, B-cell lymphoma-2 (Bcl-2)) as well as 
downregulation of apoptose inducing genes (e.g. caspase-3, Bcl-2-associated X protein 
(Bax))  [71, 72, 73]. 
 
1.2.3 Genetic Modification of Mesenchymal Stem Cells 
 
Both, preconditioning and pretreatment of MSCs have been shown to significantly influence 
gene expression patterns of the ischemic heart due to the upregulation of cytoprotective genes. 
However, both methods are unspecific which bears the risk of unwanted side effects. 
Moreover, they are potentially harmful for cells. Therefore, in recent years genetically 
modified MSCs mimicking preconditioning through expression of certain cardioprotective 
genes gained great attention for cell-based regeneration of the infarcted heart  [74]. Specific 
delivery of defined genetic materials into host cells with the objective to treat cardiovascular 
diseases is termed as cell-based gene therapy  [75]. Therefor cells are isolated, expanded in 
appropriate culture conditions and genetically manipulated. This ex vivo approach allows 
targeting of specific cell sources for gene delivery and controlled expression of certain 
proteins (e.g. growth factors). Moreover, it circumvents the safety concerns of directly 
applying viral vectors or transfection reagents in vivo  [76]. 
Cell-based gene therapy can be sub-divided into two main approaches. The first approach 
uses the genetically modified cells as a passive carrier. Therefor cells are modified in a way 
that they secret autocrine or paracrine factors to facilitate the tissue microenvironment for 
cardiac regeneration. It was shown that overexpression of heat shock protein-20 (Hsp-20) led 
to increased cell survival rates in genetically modified MSCs compared to conventional cells 
due to the activation of Akt and secretion of specific growth factors (VEGF, IGF-1, fibroblast 
growth factor-2 (FGF-2))  [77]. Moreover, our group demonstrated that overexpression of 
Bcl-2 in hMSCs led to improved cell viability and upregulated VEGF expression in vitro. In 
vivo, transplantation of Bcl-2 transfected MSCs into infarcted hearts led to increased cell 
survival and improved functional recovery  [78]. 
In the alternative approach, cells are genetically modified to optimize cell properties, e.g. 
improvement of cell viability or differentiation into a specific phenotype. It was demonstrated 
that Akt-transfected MSCs significantly decreased apoptosis and enhanced MSC engraftment. 
Moreover, VEGF, HGF and IGF-1 were upregulated within the myocardium  [79, 80]. 
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Another promising strategy is focused on the overexpression of heme oxygenase-1 (HO-1). 
HO-1 enzymatically cleaves heme to bilirubin, carbon monoxide and free iron, thus having an 
anti-oxidative, anti-apoptotic and pro-angiogenic effect. It was shown that overexpression of 
HO-1 in MSCs increased cell viability and improved heart function in vivo  [81]. Moreover, 
specific differentiation of MSCs into functional cardiomyocytes by genetic modifications 
using transcription factors is under investigation. Myocardin is a myogenic transcription 
factor regulating the expression of cardiac and smooth muscle cell genes. Grauss et al could 
show that overexpression of myocardin in hMSCs facilitated cell engraftment and induced 
differentiation towards a cardiomyocyte-like phenotype. However, electrophysiological 
analyses of hMSC derived cardiomyocytes were not investigated in this study  [82]. 
 
1.3 Different Nucleic Acid Species for Gene Therapy 
 
For gene therapy, various kinds of nucleic acids are utilized. They can be sub-divided into 
deoxyribonucleic acid (DNA)- and ribonucleic acid (RNA)- based approaches. Although, 
most of the nucleic acid-based therapeutics are in early stages of preclinical studies, these 
classes of compounds became promising candidates for treatment of a wide range of diseases, 
e.g. cardiovascular diseases, cancer, neurodegenerative diseases and genetic disorders  [74, 
75, 83, 84, 85, 86, 87, 88]. 
 
1.3.1 DNA-based Gene Therapy 
 
DNA-based gene therapy includes the application of short (e.g. DNA aptamers and 
DNAzymes) and long DNA molecules (e.g. plasmids). 
DNA aptamers are short, double-stranded DNA fragments (25-70 base pairs) that specifically 
bind proteins with high affinity. Aptamers are chemically synthesized. Therefore, they 
provide high specificity, non-immunogenicity and good stability in vivo  [89]. In 2009, Spiel 
et al tested ARC1779, a DNA-aptamer against von Willebrand factor, in blood of patients 
with acute myocardial infarction ex vivo. It was shown that ARC1779 specifically decreased 
von Willebrand factor activity. Therefore, ARC1779 could become a novel tool to reduce the 
development of myocardial infarction  [90]. 
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DNAzymes are catalytically active DNA molecules. DNAzymes bind to the target mRNA 
sequence via their binding domains. Afterwards, the catalytic domain is activated and cleaves 
the target mRNA molecule. Thus, translation into a protein is blocked  [91]. Recently, it was 
shown that a DNAzyme targeting the transcription factor early growth response protein-1 
(Egr-1) decreased inflammation and apoptosis in the heart after myocardial infarction and 
enhanced cardiac function  [92]. 
Among the DNA-based gene therapy, plasmids are predominantly used and most investigated 
for cardiac regeneration. Plasmids are circular, double-stranded DNA constructs (1 – 1,000 
kilo base pairs) encoding genes for specific proteins. After cellular internalization into the 
cytoplasm, the DNA has to enter the nucleus for efficient transcription and translation of the 
therapeutic protein. To date, various plasmid-based gene therapy studies exist to treat 
ischemic heart diseases using diverse approaches, e.g. to influence cell differentiation, 
improve angiogenesis and cell survival (summarized in  [74]). Advantageous of using 
plasmid-based gene therapy are the transfer of several genes simultaneously, the possibility of 
externally controlled gene expression (e.g. drug-sensitive promotors, hypoxia-inducible 
promotors) and better stability compared to RNA nucleotides  [93, 94, 95, 96]. However, for 
efficient gene expression foreign DNA has to cross the nuclear envelope into the nucleus 
which determines the limiting step  [97]. Moreover, the application of DNA has the risk of 
mutational insertion into the host genome which could lead to cancer  [98]. 
 
1.3.2 RNA-based Gene Therapy 
 
Regarding the drawbacks of DNA-based gene therapy, the focus has turned to RNA-based 
approaches which can be distinguished between protein coding and non-protein coding 
RNAs. To date, recent progress has been achieved in the application of coding messenger 
RNAs (mRNAs). Potential mRNA approaches have been shown for reprogramming of 
fibroblasts into iPSCs, vaccination against HIV-1 and cancer therapy  [99, 100]. However, 
further investigations have to be performed to prevent an immune response in vivo as well as 
to increase stability and efficiency of mRNAs for therapeutic applications. 
A number of current studies have shown the great influence of non-coding RNAs (ncRNAs) 
on gene expression. Only 1% to 2% of the genome is coding for proteins. The remaining 98% 
represents the big class of ncRNAs  [101]. NcRNAs are not translated into a protein but 
control various aspects of gene expression including control of transcription, post-
 1 Introduction 9 
 
 
 
transcriptional processing and epigenetic targeting  [102]. They are expressed dynamically 
during development and in response to environmental factors and stress  [103]. Regulatory 
ncRNAs can be divided into long and short ncRNAs. 
Long ncRNAs (lncRNAs) are transcripts larger than 200 nucleotides. They are involved in the 
regulation of many biological processes including chromosome X inactivation, imprinting, 
splicing and transcriptional regulation  [104, 105, 106, 107]. However, the definite function of 
most lncRNAs has to be investigated. One recent example is the lncRNA Braveheart which is 
regulating cardiac differentiation in mouse ESCs. Additionally, it was shown that Braveheart 
is also enriched in the adult heart. Therefore, it is proposed that it might be an important 
lncRNA for cardiac lineage specification and differentiation  [108]. Moreover, it was shown 
that overexpressing lncRNA-RoR modulated reprogramming of ESCs and increased the 
efficiency of iPSC-colony formation  [109]. Therefore, lncRNAs might be used to promote 
direct reprogramming of cardiac fibroblasts into cardiomyocytes. However, further studies 
have to be performed to identify potential cardiac lncRNAs for treatment of myocardial 
infarction. 
Recently, the most investigated short ncRNAs in research are small interfering RNAs 
(siRNAs) and microRNAs (miRs). SiRNAs can be used for treatment of disease causing 
genes through RNA interference (RNAi). For the discovery of RNAi, the Nobel Prize in 
Physiology or Medicine was awarded to Andrew Z. Fire and Craig C. Mello in 2006. RNAi 
provides a specific and efficient way to silence gene expression on the post-transcriptional 
level by inhibition of protein translation or direct mRNA degradation (Figure 1)  [110]. 
Primarily, siRNAs originated from exogenously introduced double stranded RNAs (dsRNAs). 
More recently, it was shown that siRNAs could arise from endogenous genomic loci as 
well  [111]. These dsRNAs are processed by Dicer into several mature siRNAs that direct 
gene silencing. SiRNAs are double-stranded nucleic acids composed of 21 – 23 nucleotides. 
After internalization into the cell, the siRNA is incorporated into a cytoplasmatic nuclease 
complex called RNA-induced silencing complex (RISC). In the RISC, Argonaute a 
catalytically active endonuclease binds to siRNA, degrades the passenger strand and leaves 
the guide strand intact to direct gene silencing. The guide siRNA strand specifically binds the 
target mRNA. Subsequently, the mRNA is cleaved and translation into a protein is stopped. 
Afterwards, the RISC is recycled and targets other mRNAs  [112]. Regarding the function of 
siRNAs, they represent a promising approach for genetic research and drug targeting. Tu et al 
investigated the effect of p53 upregulated modulator of apoptosis (PUMA) in cardiomyocytes. 
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They could demonstrate that a specific inhibition of PUMA by siRNA protects 
cardiomyocytes from apoptosis in vitro  [113]. Moreover, in vivo it was shown that the 
application of siRNA against Src homology region 2 domain-containing tyrosine 
phosphatase-1 significantly reduced apoptosis and infarction size after ischemic heart 
damage  [114]. 
The best-characterized small ncRNAs in the heart are miRs  [115]. miRs are key regulators of 
gene expression on the post-transcriptional level regulating more than 60% of all mammalian 
protein coding mRNAs  [116]. They are endogenously expressed from either miR genes or 
intronic sequences of protein coding genes in the nucleus as pri-miR (Figure 1). Subsequently, 
pri-miR is cleaved by the enzyme Drosha into a stem-loop structured precursor miR (pre-
miR). After exporting into the cytoplasm via Exportin-5, pre-miR is cleaved by the enzyme 
Dicer into one mature double-stranded miR (18 - 24 nucleotides). Mature miR enters the 
RISC where one strand is degraded while the other one interacts with the 3´untranslated 
regions of the target mRNA. Binding of RISC leads to blocking or degradation of mRNA 
translation  [117]. Thus, miRs act as inhibitors of gene expression. In contrast to siRNA, a 
single miR can bind to several target genes connected with the potential to modulate multiple 
cell pathways. Eulalio et al could demonstrate that none of the investigated siRNAs could 
increase the proliferation of cardiomyocytes as highly as observed with miRs. They concluded 
that the remarkable effect of these miRs might be a cumulative effect on multiple, cellular 
mRNA targets  [118]. Moreover, it is supposed that miR-based gene therapy might be less 
harmful for cells compared to siRNA treatment as it is closer to the innate regulation 
mechanism  [119]. 
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Figure 1: Biogenesis and Function of miR and siRNA. MiRs are expressed in the nucleus as pri-
miR where they are subsequently cleaved by enzyme Drosha to stem-loop pre-miRs. Afterwards, the 
pre-miR is transferred via Exportin-5 into the cytoplasm where it is further processed by Dicer into a 
mature miR duplex. The functional miR strand is assembled in the RISC and thus able to repress 
translation of a set of mRNAs or to cleave the mRNA targets. SiRNA is mostly exogenously 
introduced into the cytosol as dsRNA. Then it is cleaved by Dicer into siRNA and is assembled in the 
RISC comparable to miR processing. However, siRNA perfectly matches to its specific target mRNA 
via Watson-Crick base pairing leading to inhibition of mRNA (taken from  [120]). 
To date, several miRs have been discovered that control cell differentiation, growth, 
proliferation and apoptosis  [121, 122, 123]. In particular miRs play an essential role in heart 
development and cardiac diseases  [124, 125]. The significance of miRs in cardiovascular 
development was demonstrated in Dicer-deficient mice where miR biogenesis was blocked. 
These mice showed seriously impaired heart and vessel development and died between days 
12.5 and 14.5 of gestation  [126]. Moreover, miRs show typical expression patterns after 
myocardial infarction, e.g. deregulated expression of miR-21, miR-1, miR-216 and miR-29 
family  [127, 128]. In addition, members of the miR-15 family (miR-15a, miR-15b, miR-16-1, 
miR-16-2, miR-195 and miR-497) were upregulated after ischemic damage in the heart 
resulting in death of cardiomyocytes and loss of pump function  [129]. 
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To date, different miR modulation strategies are available to treat myocardial infarction. The 
first possibility includes the inhibition of pathogenic miRs. Therefor miR inhibition can be 
achieved by the application of antagomiRs. AntagomiRs are small RNA oligonucleotides that 
perfectly match to the complementary miR. They are used to specifically silence endogenous 
miRs. It was shown that miR-15 inhibition reduced infarction size and improved cardiac 
function 2 weeks after myocardial infarction  [130, 131]. Moreover, Bonauer et al showed 
that systemic administration of an antagomir-92a increased angiogenesis and functional 
recovery of the damaged tissue after myocardial infarction  [132]. Recently, it was 
demonstrated that inhibition of miR-34a improved cell survival and heart functions following 
heart infarction by reducing telomere shortening, DNA damage responses and cardiomyocyte 
apoptosis  [133]. Additionally, overexpression strategies of miRs are investigated. It was 
shown, that overexpression of miR-210 enhanced angiogenesis, inhibited apoptosis and 
improved cardiac function after myocardial infarction  [134]. Recently, exogenously 
introduced miR-199a and miR-590 have been found to stimulate cardiac regeneration after 
heart infarction in mice  [118]. Additionally, novel approaches to combine stem cell- and 
miR-based therapies are examined (Figure 2). It was shown, that overexpression of miR-499 
in bone marrow MSCs increased the expression of cardiac specific genes (Nkx2.5, GATA4 
and MEF2C) and induced cardiac differentiation  [135]. In 2013, Huang et al overexpressed 
miR-1 in MSCs prior to transplantation in the infarcted heart. They could demonstrate 
enhanced survival of transplanted cells and cardiomyogenic differentiation thus improving 
heart function  [136]. Recently, Dakhlallah et al showed that transfection of MSCs with miR-
133a improved survival of MSCs in vitro. Moreover, transplantation of miR-133a modified 
MSCs in the heart led to a significant enhanced cell engraftment, cardiac function and 
decreased fibrotic remodeling after myocardial infarction by targeting pro-apoptotic genes 
(Apaf-1, caspase-9, caspase-3)  [137]. Therfore, miR modified MSCs represent potential 
novel therapeutic approaches for treatment of ischemic heart diseases. 
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Figure 2: Ex Vivo Genetic Modifications of hMSCs using miRs. (I) hMSCs were obtained and 
purified from bone marrow aspirates. (II) Afterwards, freshly isolated or expanded hMSCs were 
genetically modified with miRs using viral transduction or non-viral transfection in vitro. (III) 
Subsequently, the modified cells were injected in the infarcted heart to improve tissue regeneration 
(data are summarized from  [123, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144]). 
 
1.4 Small RNA-Based Delivery Methods 
 
Genetic modifications of MSCs using miRs have been shown to enhance the efficiency of 
stem cell therapy by influencing cell viability, differentiation and secretion of paracrine 
factors  [145]. Various artificial precursor or mature miRs are commercially available. 
However, reduced in vivo stability, inappropriate biodistribution and unwanted side effects are 
limitations of successful miR-based therapy  [146]. Therefore, safe and efficient miR transfer 
methods suitable for clinical applications have to be developed. To date, two delivery 
approaches are under investigation: viral and non-viral delivery methods. 
Viruses are naturally evolved nano-scaled vehicles (viral vectors) that efficiently transfer their 
genes into host cells. They are the most efficient vectors to deliver DNA both in vivo and in 
vitro  [147, 148, 149]. Advantages of using viral vectors are high transduction efficiencies and 
stable gene expression. However, the possibility of insertional mutagenesis, pathogenic vector 
mutation, cytotoxicity and immunogenicity limit the clinical use of this carrier  [146, 150]. 
For investigating the regulatory role of miRs, primarily lentiviruses, adenoviruses and adeno-
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associated viruses are used. However, none of these viral vectors deliver miR itself. All 
studies use miR expressing vectors like DNA sequences that require nuclear localization for 
efficient transcription into pri-miR and further processing by the RNA machinery  [118, 133, 
151, 152, 153, 154, 155]. Therefore, this belongs to the field of DNA delivery. 
 
1.4.1 Non-Viral Delivery Methods 
 
Non-viral delivery methods were developed to overcome the drawbacks of viral vectors. They 
show less safety risks, high nucleic acid capacity, non-inflammatory and non-infectious 
behaviour  [156]. Moreover, miRs and siRNAs can be delivered in their mature structure. In 
contrast to viral vectors, plasmid-based gene expression or RNAi is often transient which 
might be preferable due to a better control of the therapeutic effect  [157]. In general, all non-
viral transfection techniques can be divided into physical and chemical methods. 
Over the past years, many physical methods have been investigated for gene delivery, e.g. 
electroporation, gene gun, sonoporation and microinjections. Recent developments propose 
that gene delivery using physical methods has reached the efficiency and expression duration 
that is clinically meaningful  [158]. Here, physical forces (e.g. injection, particle impact, 
electric pulse, ultrasound or laser irradiation) are used to facilitate the transfer of nucleic acids 
inside the cell by creating transient membrane defects  [150]. Primarily, electroporation which 
uses an electric field to generated transient pores in the cell membrane for nucleic acid entry 
is used  [159, 160]. Tano et al could efficiently block miR-150 in bone marrow derived 
mononuclear cells by transferring the appropriate antagomiR using electroporation  [161]. 
However, physical methods are potentially damaging cells due to deregulated ion influx or 
thermal heating. Moreover, application of naked small RNAs inside the cell is susceptible to 
the degradation by nucleases  [162]. Additionally, all physical methods are preferentially used 
for ex vivo modulation of cells. In vivo applications are limited due to the accessibility to the 
internal organs. 
Chemical methods use cationic synthetic or natural compounds to condense and protect 
negatively charged nucleic acids  [150]. They show great potential as effective carriers for 
DNA, siRNA and miR  [156, 163, 164]. Advantages of using chemical methods include the 
control of their molecular composition and their simplified manufacturing  [165]. The most 
commonly used chemical transfection reagents are cationic lipids and cationic polymers. 
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In 1987, Felgner et al were the first who described cationic lipid-based gene delivery. They 
introduced the term lipofection which describes a lipid-based transfection procedure for 
nucleic acids  [166]. Cationic lipids build vesicles composed of a phospholipid bilayer with an 
aqueous core. Moreover, they have the ability to build complexes with negatively charged 
nucleic acids through electrostatic interactions - so called lipoplexes  [150]. The cellular 
pathway of lipoplexes was revealed by Xu et al in 1996. After association of cationic 
liposome/DNA complexes to the negatively charged cell membrane, lipoplexes were 
incorporated into the cell via endocytosis. In the early endosome, the endosomal membrane 
was destabilized by a flip-flop mechanism of anionic phospholipids. The anionic membrane 
lipids laterally diffused into the lipoplexes and formed neutrally charged ion pairs with the 
cationic lipids of the lipoplexes. As a result, DNA was released from the lipoplexes allowing 
cytoplasmatic entry  [167]. Currently, there are several lipid-based delivery systems 
commercially available like Lipofectamine
®
 (Invitrogen). Lipofectamine
® 
is a mixture of the 
cationic lipid 2,3-dioleoyloxy-N-[2-(spermine-carboxamido)ethyl]-N,N-dimethyl-1-
propanaminium trifluoroacetate (DOSPA) and neutral helper lipid dioleoyl 
phosphatidylethanolamine (DOPE). Alaiti et al used Lipofectamine
®
 to transfect CD34
+
 
hematopoietic stem cells with miR-210 in vitro. They could demonstrate up to 60% 
transfection efficiency and good cell viability (87%)  [168]. To date, lipofection belongs to 
the most extensively investigated and frequently used non-viral gene delivery methods in 
vitro. It provides several commercially available products with highly efficient gene delivery 
of both DNA and small RNAs connected with low costs  [169]. However, safe and efficient 
delivery in vivo is restricted due to cytotoxicity, nonspecific uptake and unwanted immune 
response  [170]. 
Cationic polymers represent an additional class of chemically based non-viral vectors with 
high transfection efficiency. One of the most widely used cationic polymer in vitro and in vivo 
is polyethylenimine (PEI)  [171, 172, 173]. PEI consists of several units of two carbons and 
one nitrogen atom. Under physiological conditions, high amounts of amino groups in PEI are 
protonated providing its positive surface charge and good buffering capacity. Thus, PEI can 
be used to condense nucleic acids and form cationic complexes (termed as polyplexes) 
through electrostatic interactions  [146]. Positively charged polyplexes can interact with 
negatively charged polysaccharides of the cell membrane. Once bound to the cell surface, it is 
proposed that polyplexes are taken up inside the cell via endocytosis  [171]. In 1995, Boussif 
et al investigated the intracellular pathway of polyplexes and revealed the endosomal escape 
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mechanism of PEI polyplexes through ‘proton sponge’ effect as crucial step for efficient 
transfection  [174]. During the endosomal maturation, the membrane-bound ATPase actively 
pumps protons from the cytosol into the endosomes leading to acidification of endosomal 
compartments and activation of hydrolytic enzymes. Additionally, incorporated polyplexes 
get protonated and resist acidification. Subsequently, more protons are transported into the 
endosomes to decrease the pH value. This leads to a passive entry of chloride ions and an 
increase of ionic concentration followed by a passive water influx. Subsequently, the osmotic 
pressure inside the vesicles increases and causes swelling and rupture of the endosomal 
membrane releasing polyplexes into the cytoplasm  [174, 175]. Thus, nucleic acids are 
protected from lysosomal degradation. Urban-Klein et al successfully developed a PEI-based 
siRNA delivery approach. They could demonstrate that PEI efficiently protects siRNA against 
enzymatic degradation. Moreover, it was shown that siRNA/PEI complexes but not siRNA 
alone could deliver functional siRNA both in vitro and in vivo resulting in a significant 
reduction of human epidermal growth factor receptor-2 (HER-2) mRNA levels (~ 50%) 
compared to the untransfected group  [172]. Additionally, Ibrahim et al demonstrated that PEI 
is also able to form stable complexes with miR and could efficiently transfect more than 80% 
of cells  [176]. Although, cytotoxicity and non-biodegradability of PEI restrict its clinical 
applications  [177], Grayson et al demonstrated that branched PEI with a molecular weight of 
25 kDa was the most successfully tested polymer for siRNA delivery in vitro  [178]. 
However, for directed miR delivery in vivo, PEI polyplexes are limited due to the lack of 
specificity. Therefore, specific targeting approaches could be applied to overcome these 
obstacles. 
 
1.4.2 Magnetic Gene Targeting Strategies 
 
To date, numerous non-viral approaches for gene delivery are under investigations. However, 
there is still no perfect nano-scaled delivery system available, which achieves efficient, safe 
and selective delivery of the genetic material for translation into the clinic. Different targeting 
strategies have attracted attention as they provide specific and local gene delivery proposed 
for systemic administration. Targeted RNAi can be achieved either by functionalization of the 
non-viral vector with specific ligands (e.g. peptides, growth factors, antibodies) or by 
combination with magnetic nanoparticles (MNPs) which can be guided by an external 
magnetic field  [179, 180, 181, 182, 183, 184]. MNPs have already been used for MACS, 
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hyperthermia for cancer treatment, protein purification and cell tracking  [185, 186, 187, 188]. 
Additionally, iron oxide-based MNPs were approved by the US Food and Drug 
Administration as magnetic resonance imaging (MRI) contrast agents (Resovist
®
, Feridex 
IV
®
)  [189]. Therefore, they have been well characterized in terms of biocompatibility and 
safety issues being essential for potential clinical applications. Moreover, the surface of 
MNPs can be functionalized with surfactants, ligands or biomolecules, e.g. streptavidin 
coating  [190]. Additionally, size, charge and magnetic properties of MNPs can be modified 
during their production  [189]. Previous studies have shown that MNP-mediated gene delivery 
enables both in vivo targeting of the magnetic complexes towards a specific organ and guiding 
of cells transfected with MNPs using an externally applied magnetic field  [183, 191]. 
Therefore, it was proposed that a combination of MNPs with different non-viral gene delivery 
methods can be a promising strategy to increase their selectivity and efficiency. 
In 2002, Scherer et al demonstrated a new technique called magnetofection, where common 
viral and non-viral gene delivery agents (e.g. adenovirus, Lipofectamine
®
, PEI) were 
combined with paramagnetic iron oxide nanoparticles via salt-induced aggregation. It was 
shown that an externally applied magnetic field increased sedimentation of the transfection 
complexes and efficiently improved transfection efficiency in vitro and in vivo  [192]. 
However, magnetofection is not facilitating cellular uptake or intracellular pathways  [193]. In 
recent years, MNP-mediated transfection (e.g. Magnetofectamine
®
) has become a powerful 
approach for highly effective and fast delivery of both DNA as well as siRNA  [194, 195, 
196, 197, 198]. Tan et al successfully delivered siRNA using Magnetofectamine
®
-based 
transfection which is a combination of the cationic lipid Lipofectamine
®
 from Invitrogen with 
PEI-coated CombiMag MNPs from OZ Biosciences. They could demonstrate transfection 
efficiencies between 70% to 90% in a mouse N2A neuroblastoma cell line and 15% to 30% in 
primary neurons  [199]. 
A different approach for magnetically targeted DNA transfection has been developed by our 
group in 2008. Li et al first condensed DNA by biotinylated PEI to form DNA/PEI 
polyplexes. Afterwards, DNA/PEI complexes were covalently bound to streptavidin-coated 
MNPs via biotin-streptavidin connections (Figure 3). In vitro, it was shown that reporter gene 
expression was up to 85-fold increased after transfection with magnetic polyplexes compared 
to DNA/PEI complexes alone in different cell lines (NIH3T3, HEK293, COS7) as well as in 
primary endothelial cells using magnetic forces. Moreover, DNA/PEI/MNP complexes were 
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further applied in vivo. After intravenous injection in the tail vein of mice, magnetic 
polyplexes could be targeted to the heart by an external magnetic field  [200]. 
 
 
Figure 3: Construction of Magnetic Transfection Complexes. Negatively charged nucleic acids 
(e.g. DNA or miR) form complexes with biotinylated cationic PEI due to electrostatic interactions. 
Afterwards, PEI polyplexes are covalently bound to streptavidin coated paramagnetic iron oxide 
nanoparticles via streptavidin-biotin connections (adopted from  [201]). 
 
Recently, we have shown enhanced transfection efficiencies for DNA-based complexes after 
MNP-based transfection in hMSCs even without the application of a magnetic field  [202]. 
Therefore, Delyagina et al proposed different transfection mechanisms for DNA/PEI/MNP 
and DNA/PEI complexes. It is assumed that MNP-bound polyplexes provide a faster release 
of DNA into the cytosol compared to PEI polyplexes. Furthermore, DNA/PEI/MNP 
complexes remain outside the nucleus due to the strong biotin-streptavidin binding between 
PEI and MNPs while condensed polyplexes were found inside the nucleus  [202, 203]. Thus, 
MNP-containing complexes may be advantageous for miR delivery as opposed to DNA, miR-
mediated RNAi takes place in the cytosol. 
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1.5 Aim of the Thesis 
 
Based on the background described above, the aim of this thesis was to develop a non-viral 
miR delivery vector for efficient modification of freshly isolated hMSCs using magnetic 
miR/PEI/MNP complexes and show proof-of-principle for targeting of transfected hMSCs by 
an externally applied magnet in vitro. Initially, the optimal complex composition had to be 
found in expanded hMSCs by investigating different miR amounts, PEI concentrations and 
MNP quantities. In this study, delivery of miR-335 was chosen as exemplary model. MiR-335 
had been shown to influence proliferation, differentiation and migration of hMSCs by 
targeting tenascin C (TNC) and runt-related transcription factor 2 (RUNX2), 
respectively  [144]. Then, the intracellular processing of transfected pre-miR-335 into mature 
strand, RNAi of known target genes as well as functionality of delivered miR was 
investigated. Subsequently, the optimized magnetic vector should be applied to freshly 
isolated hMSC as they bear less safety risks and more relevance for clinical applications. 
Moreover, transfection performance of miR/PEI/MNP complexes should be compared to 
commonly used and commercially available magnetic vectors. Finally, the ability to 
specifically target magnetically transfected hMSCs using an externally applied magnetic field 
was investigated in vitro. 
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2 Materials and Methods 
 
2.1 List of Chemicals 
 
Table 1: List of Chemicals Used in this Thesis 
Manufacturer Chemicals 
ATTO-TEC GmbH, Siegen, Germany Atto 565 Biotin 
Biozym Scientific GmbH, Hessisch 
Oldendorf, Germany 
Agarose 
Carl Roth, Karlsruhe, Germany Boric Acid 
DMSO 
NaCl 
TRIS 
Fermentas GmbH, Schwerte, Germany 6x DNA Loading Dye 
Life Technologies Corporation, Austin, 
USA 
Acid-Phenol Chloroform 
Cy3™ dye-Labeled Pre-miR Negative  
Control #1 
DAPI 
UltraPure™ DNase/RNase-free Distilled Water 
hsa-miR-335-5p Pre-miR™ miRNA Precursor 
Lipofectamine
®
 2000 
Opti-MEM
®
 I Reduced Serum Medium 
Pre-miR™ miRNA Precursor Molecules - 
Negative Control #1 
Recovery™ Cell Culture Freezing Medium 
TaqMan
®
 2x Universal PCR Master Mix with 
AmpErase
®
UNG 
α-MEM 
Lonza, Walkersville, USA MSCGM™ 
Merck, Darmstadt, Germany FluorSave™ 
Merck Millipore, Billerica, USA Human Plasma Fibronectin 
Miltenyi Biotec GmbH, Bergisch-Gladbach, 
Germany 
CD105 MicroBeads 
FcR Blocking Reagent 
MP Biomedicals, Solon, USA Glucose 
OZ Biosciences, Marseille, France CombiMag Reagent 
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PAA Laboratories GmbH, Pasching, Austria EDTA 
Penicillin 
Streptomycin 
Trypsin/EDTA (10x) 
Pan Biotech GmbH, Aidenbach, Germany FBS 
Pancoll Separation Medium 
PBS 
RPMI 1640  
Promega, Madison, WI, USA Streptavidine Magnesphere
®
 Paramagnetic 
Particles 
Roche Diagnostics GmbH, Mannheim, 
Germany 
Collagenase B 
DNase I 
Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
BSA 
Donkey Serum 
Ethidium Bromide 
Glycine 
Ninhydrin Reagent 
PEI 25 kDa 
PFA 
Triton X-100 
Trypan Blue 
Thermo Fisher Scientific, Rockford, USA Sulfo-NHS-LC-Biotin Linker 
Zentralapotheke der Universitätsmedizin 
Rostock, Rostock, Germany 
Ethanol Absolute 
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2.2 List of Solutions 
 
Table 2: List of Solutions Used in this Thesis 
Solution Contents 
α-MEM Basal Medium 90% α-MEM 
10% FBS 
100 U/ml Penicillin  
100 μg/ml Streptomycin 
Adipogenic Differentiation Medium 99% α-MEM Basal Medium 
1% Adipogenic Supplement  
Adipogenic Supplement Hydrocortisone 
Indomethacin 
Isobutylmethylxanthine 
Blocking Solution 0.3% Triton X-100  
1% BSA 
10% Donkey Serum  
PBS 
MACS-Buffer 0.5% BSA 
2mM PBS/EDTA 
MSCGM™ 500 ml MSCBM 
50 ml MCGS 
10 ml L-Glutamine 
0.5 ml GA-1000 
100 U/ml Penicillin 
100 μg/ml Streptomycin 
Osteogenic Differentiation Medium 95% α-MEM Basal Medium 
5% Osteogenic Supplement 
Osteogenic Supplement  Ascorbatephosphate 
Dexamethasone 
β-Glycerolphosphate 
TBE Buffer 54 g TRIS 
27.5 g Boric Acid 
20 ml of 0.5 M EDTA 
Adjust to pH 8.0 
Up to 1 l with dH2O 
 
Washing Solution 1% BSA 
PBS 
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2.3 hMSC Isolation and Culture 
 
hMSCs derived from bone marrow were obtained from sternal aspirates of patients 
undergoing artery bypass surgery at the Cardiac Surgery Department of the University of 
Rostock as described previously  [204]. The donors gave their written consent to use their 
bone marrow for research purposes according to the Declaration of Helsinki. 
 
2.3.1 Isolation of Mononuclear Cells 
 
Mononuclear cells (MNCs) were isolated by density gradient centrifugation. Therefor, 10 ml 
of bone marrow aspirates were mixed with 6 ml phosphate buffered 
saline/ethylenediaminetetraacetic acid solution (PBS/EDTA), 20 ml RPMI 1640 medium,  
175 µl collagenase B (0.02%) and 175 µl DNase I (100 U/ml) and incubated on the shaker 
(VWR International GmbH, Darmstadt, Germany) for 30 minutes at room temperature. 
Meanwhile, 15 ml Pancoll separation medium was pipetted into 50 ml Leucosep
®
 tubes 
(Greiner Bio-One GmbH, Solingen, Germany) with subsequent centrifugation at 1,000 g for 
10 seconds. After the incubation time, the cell suspension was transferred to the prepared 
Leucosep
®
 tubes (Greiner Bio-One) and centrifuged at 445 g for 35 minutes at 22 °C. After 
aspiration of the MNC layer, the volume of the cell suspension was adjusted to 50 ml with 
PBS/EDTA solution and centrifuged at 300 g for 10 minutes at 22 °C. Then, cell numbers 
were determined and up to 1.5x10
8
 MNCs per 175 cm
2
 culture flask (Greiner Bio-One) were 
cultivated in 20 ml Mesenchymal Stem Cell Growth Medium (MSCGM™) at 37 °C and 5% 
CO2. 
 
2.3.2 Isolation of hMSCs by Plastic Adherence 
 
For plastic adherence selection of hMSCs, the cell suspension was cultivated in MSCGM™ at 
37 °C and 5% CO2 until the adherent hMSC population reached 80% confluency. 
Subsequently, the cells were passaged or frozen in 1 ml Recovery™ Cell Culture Freezing 
medium at -170 °C in liquid nitrogen. For transfection optimization experiments using 
expanded cells, hMSCs in passage 3 and 4 were used. The morphology of the cells was 
analyzed using an Axiovert 40 CFL microscope (Carl Zeiss AG, Jena, Germany). 
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2.3.3 Isolation of hMSCs by Magnetic Cell Separation 
 
For magnetic cell separation of CD105
+
 hMSCs from the MNC fraction (cultivated 
overnight), MACS
®
 technology was applied according to the manufacturer’s protocol 
(Miltenyi Biotec GmbH, Bergisch-Gladbach, Germany). Briefly, MNC suspension was 
centrifuged at 300 g for 10 minutes at 4 °C and supernatant was discarded. Afterwards, 1x10
7
 
MNCs were resuspended in 60µl MACS-buffer. For magnetic cell labeling, the cell 
suspension was mixed with 20 µl FcR Blocking Reagent and 20 µl CD105 MicroBeads and 
incubated for 30 minutes at 4 °C. In the case of higher cell numbers, volume of reagents was 
scaled up accordingly. Afterwards, cells were washed with 2 ml MACS-buffer and 
centrifuged at 200 g for 10 minutes at 4 °C. Supernatant was removed and the cell pellet was 
resuspended in 500 µl MACS-buffer. Next, the magnetically labeled cell suspension was 
filtered through a 30 µm pre-separation filter (Miltenyi Biotec) to remove cell aggregates. 
Subsequently, the cell suspension was applied to equilibrated MS (up to 2x10
8
 MNCs) or LS 
(2x10
8
 - 2x10
9
 MNCs) MACS
®
 columns (Miltenyi Biotec) under the application of a 
magnetic field using a MiniMACS
®
 or MidiMACS
®
 separator (Miltenyi Biotec). Afterwards, 
columns were washed three times with 500 µl MACS-buffer for MS MACS
®
 column or 3 ml 
MACS-buffer for LS MACS
®
 column, respectively. After removing the magnetic field, the 
magnetically labeled CD105
+
 cell fraction was eluted with 1 ml MSCGM™ for MS MACS® 
columns or 3 ml MSCGM™ for LS MACS® columns. To increase cell purity, the isolation 
process was repeated using a second rinsed MS or LS MACS
®
 column, respectively. 
Subsequently, the number of living cells was determined by trypan blue staining (0.4%) and 
the cell morphology was analyzed using an Axiovert 40 CFL microscope (Carl Zeiss). For 
further in vitro experiments using freshly isolated cells, the positive CD105
+
 cell fraction was 
suspended in MSCGM™ and was transfected immediately after isolation. 
 
2.4 Immunophenotyping of hMSCs 
 
Cell surface markers of freshly isolated and cultured hMSCs were fluorescently labeled with 
anti-human antibodies CD29-APC, CD44-PerCP-Cy5.5, CD45-V500, CD73-PE, CD117-PE-
Cy7 (BD Biosciences, Heidelberg, Germany) and CD105-AlexaFluor488 (AbD Serotec, 
Kidlington, UK). Appropriate mouse isotype antibodies served as negative controls. 
Therefore, 5x10
4
 hMSCs were labeled with respective fluorescent dye-conjugated antibodies 
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(Table 3). The total volume was adjusted to 100 µl with MACS-buffer and the cells were 
incubated in the dark for 10 minutes at 4 °C. After the incubation time, cells were washed 
with 1 ml PBS and centrifuged at 300 g for 10 minutes. Supernatant was discarded and the 
cell pellet was resuspended in 100 μl PBS and 33 µl paraformaldehyde (4% PFA). 
Subsequently, 2x10
4
 cells were acquired using a BD FACS LSRII™ flow cytometer (BD 
Biosciences) and analyzed with BD FACSDiva Software 6 (BD Biosciences). 
 
Table 3: Immunofluorescent Labeling of hMSCs 
Antigen Dye Company 
Catalogue 
number 
V (dye) 
per 100 µl 
CD29 APC BD Biosciences 559883 10 µl 
CD44 PerCP-Cy5.5 BD Biosciences 560531 2.5 µl 
CD45 V500 BD Biosciences 560777 2.5 µl 
CD73 PE BD Biosciences 550257 10 µl 
CD105 AF 488 AbD Serotech MCA1557A488 5 µl 
CD117 PE-Cy7 BD Biosciences 339217 2.5 µl 
Isotype control CD29 APC BD Biosciences 555751 10 µl 
Isotype control CD44 PerCP-Cy5.5 BD Biosciences 558304 10 µl 
Isotype control CD45 V500 BD Biosciences 560787 2.5 µl 
Isotype control CD73 PE BD Biosciences 555749 10 µl 
Isotype control CD105 AF 488 AbD Serotech MCA928A488 5 µl 
Isotype control CD117 PE-Cy7 BD Biosciences 557872 2.5 µl 
 
2.5 Functional Differentiation Assay 
 
The differentiation capacity of hMSCs was analyzed using the Human Mesenchymal Stem 
Cell Function Identification Kit (R&D Systems, Minneapolis, USA). 
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2.5.1 Adipogenic Differentiation of hMSCs 
 
For adipogenic differentiation, 5x10
4
 cells per well were expanded in a 24-well plate on 
sterilized coverslips (Carl Roth) in α-Minimum-Essential-Medium (α-MEM) Basal Medium 
at 37 °C and 5% CO2. When 100% confluency was reached, the cells were cultivated in 
Adipogenic Differentiation Medium (R&D Systems). Differentiation Medium was changed 
every 3 to 4 days. After 20 days under differentiation conditions, cells were washed twice 
with 1 ml PBS and fixed with 500 µl PFA (4%) for 20 minutes at room temperature. Next, the 
cells were washed three times for 5 minutes with 500 µl washing solution. Afterwards, 
hMSCs were permeabilized and blocked with 500 µl blocking solution. Subsequently, 
staining for adipogenic differentiation was performed. Therefor, 300 µl per well of goat anti-
mouse fatty acid binding protein-4 (FABP-4) primary antibody (10 µg/ml, R&D Systems) 
were incubated overnight at 4 °C. Then, the cells were washed three times for 5 minutes with 
500 µl washing solution. Afterwards, 300 µl of Alexa Fluor 488 donkey anti-goat IgG 
secondary antibody (Life Technologies) diluted 1:200 in washing solution was incubated in 
the dark for 1 hour at room temperature. Cells were washed three times with 500 µl washing 
solution and stained with 300 µl 4',6-diamidino-2-phenylindole (DAPI) dihydrochloride   
(250 nM) in the dark for 15 minutes at room temperature. After three washing steps with 1 ml 
PBS on the microplate shaker (Grant Instruments, Cambridge, England), coverslips were 
mounted with FluorSave™ on a microscope slide (Paul Marienfeld GmbH & Co. KG, Lauda-
Königshofen, Germany). Images were acquired using an ELYRA PS.1 LSM 780 microscope 
(Carl Zeiss) and analyzed by ZEN2011 software (Carl Zeiss, Göttingen, Germany). 
 
2.5.2 Osteogenic Differentiation of hMSCs 
 
For osteogenic differentiation, 3x10
4
 hMSCs per well were seeded in 500 µl α-MEM Basal 
Medium on human plasma fibronectin (10 µg/ml) coated coverslips and incubated at 37 °C 
and 5% CO2 until 50% to 70% confluency was reached. Subsequently, the cells were 
cultivated in Osteogenic Differentiation Medium (R&D Systems). Osteogenic Differentiation 
Medium was exchanged every 3 to 4 days. After 20 days in differentiation medium, the cells 
were fixed and stained as described above (see 2.5.1) using mouse anti-human osteocalcin 
primary antibody (R&D Systems) and Alexa Fluor 488 donkey anti-mouse IgG (Life 
Technologies). 
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2.6 Preparation of Transfection Complexes 
 
2.6.1 Preparation of Polyplex-based Transfection Complexes 
 
For preparation of miR/PEI, miR/PEI/MNP and miR/PEI/CombiMag complexes, Cy3™ dye-
Labeled Pre-miR Negative Control #1, Pre-miR™ miRNA Precursor Molecules - Negative 
Control #1 or hsa-miR-335-5p Pre-miR™ miRNA Precursor were used. MiRs were diluted in 
100 µl DNase/RNase free distilled water and stored in aliquots with a concentration of 50 mM 
at -20 °C. 
Branched PEI (25 kDa) was biotinylated using a Sulfo-NHS-LC-Biotin linker and was kindly 
provided by Natalia Voronina (University of Rostock, Germany). To determine the 
biotinylation degree of PEI, EZ Biotin Quantitation Kit (Thermo Fisher Scientific) was used 
according to the manufacturer’s protocol. PEI with 1.3 mMol Biotin/mMol PEI was obtained. 
To measure the α-amino group concentration in PEI, Ninhydrin reagent solution (2%) was 
used. Therefor 100 µl of PEI solution and 75 µl of Ninhydrin reagent were mixed and 
incubated for 30 minutes at 80 °C. Afterwards, 100 µl ethanol absolute were added and 
absorbance of PEI samples was measured at 550 nm against glycine standard curve of known 
concentrations. Biotinylated PEI was stored at amine concentrations of 27.6 mM at 4 °C. 
 
2.6.1.1 Preparation of miR/PEI Complexes 
 
For preparation of miR/PEI complexes, different molar ratios of PEI nitrogen and miR 
phosphate (NP ratios) were prepared (Equation 1). Therefor miR and PEI were diluted in 
equal volumes of 5% glucose solution, well mixed and incubated for 30 minutes at room 
temperature (Table 4, 5). 
 
          
  (   )    (   )
       (   )
 
 
Equation 1: Calculation of the NP Ratio Referring to the Number of Nitrogen Atoms (N) in PEI 
per Phosphate Group (P) of miR (C (PEI) = concentration of amine nitrogen in PEI in mM,             
V (PEI) = volume of PEI in µl, n (miR) = amount of substance of miR in pmol, 0.12 nmol/pmol = 0.12 
nmol of phosphate in 1 pmol of miR). 
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Table 4: Transfection Protocol for Cultured hMSCs. Values are calculated according to 5pmol/cm² 
of miR. (n (miR) = amount of substance of miR, NP = number of N in PEI per P of miR,                     
V (PEI) = volume of PEI, V (glucose) = volume of glucose for miR and PEI dilution). 
Culture 
plate 
Cell 
number/ 
well n (miR) 
V (PEI) 
V 
(glucose) NP 2.5 NP 5 NP 10 
24-well 15,000 5 pmol 0.05 µl 0.11 µl 0.22 µl 50 µl 
12-well 30,000 10 pmol 0.11 µl 0.22 µl 0.44 µl 100µl 
6-well 100,000 50 pmol 0.54 µl 1.09 µl 2.17 µl 200 µl 
 
Table 5: Transfection Protocol for Freshly Isolated hMSCs. (n (miR) = amount of substance of 
miR, NP = number of N in PEI per P of miR, V (PEI) = volume of PEI, V (glucose) = volume of 
glucose for miR and PEI dilution). 
Culture 
plate 
Cell 
number/ 
well n (miR) 
V (PEI) 
V 
(glucose) NP 2.5 NP 5 NP 10 
48-well 
200,000 5 pmol 0.05 µl 0.11 µl 0.22 µl 50 µl 
200,000 10 pmol 0.11 µl 0.22 µl 0.44 µl 50 µl 
12-well 500,000 10 pmol - - 0.44 µl 100 µl 
 
2.6.1.2 Preparation of miR/PEI/MNP Complexes 
 
For the formation of miR/PEI/MNP complexes, Streptavidine Magnesphere
®
 Paramagnetic 
Particles (in the following abbreviated as MNPs) were used. First, MNPs were sonicated and 
filtered using a 450 nm Millix-HV PVDF syringe driven filter (Millipore, Tullagreen, 
Ireland). Then, the iron concentration of the MNP solution was determined by measuring the 
absorbance at 351 nm with a spectrophotometer (Themo Electron, Waltham, USA) against 
iron standard solution of known concentrations. The MNP filtrate was stored in aliquots at     
4 °C. After the preparation of miR/PEI complexes, 1 to 6 μg/ml iron in sonicated MNPs were 
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added and incubated for 30 minutes at room temperature. miR/PEI and miR/PEI/MNP 
complexes were freshly prepared before each transfection experiment. 
 
2.6.1.3 Preparation of miR/PEI/CombiMag Complexes 
 
In order to form miR/PEI/CombiMag complexes, Cy3™ dye-Labeled Pre-miR Negative 
Control #1 was used. At first, CombiMag reagent was incubated for 20 minutes in an 
ultrasonic bath (Bandelin electronic GmbH & Co. KG, Berlin, Germany). Subsequently, 
0.025 µl CombiMag per 1 pmol miR were mixed with miR/PEI complexes. 
miR/PEI/CombiMag complexes were incubated for 20 minutes at room temperature. 
Transfection complexes were freshly prepared before transfection. 
 
2.6.2 Preparation of Lipoplex-based Transfection Complexes 
 
2.6.2.1 Preparation of miR/Magnetofectamine® Complexes 
 
For the preparation of miR/Magnetofectamine
®
 complexes, Cy3™ dye-Labeled Pre-miR 
Negative Control #1 was used. Initially, miR/Lipofectamine
®
 complexes were formed. 
Therefor miR and Lipofectamine
®
 2000 transfection reagent (0.05 µl 
Lipofectamine
®
2000/pmol miR) were diluted each in 25 µl of Opti-MEM
®
 I Reduced Serum 
Medium and incubated for 5 minutes at room temperature. Afterwards, miR solution and 
Lipofectamine
®
 solution were mixed and incubated for 20 minutes at room temperature. In 
order to form miR/Magnetofectamine
®
 complexes, CombiMag reagent was sonicated for 20 
minutes. Then, 0.025 µl CombiMag/pmol miR were mixed with miR/Lipofectamine
®
 
complexes and incubated for 20 minutes at room temperature. MiR/Magnetofectamine
®
 
complexes were freshly prepared before use. 
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2.7 Characterization of miR/PEI and miR/PEI/MNP Complexes 
 
2.7.1 Condensation Assay 
 
Condensation of miR by PEI was evaluated by gel electrophoresis. Therefor miR and 
miR/PEI complexes composed of 20 pmol Pre-miR™ miRNA Precursor Molecules - 
Negative Control #1 with NP ratios ranging from 0.1 to 33 were prepared as described above 
(see 2.6.1.1). Afterwards, the samples were mixed with 2.5 µl 6x loading dye and loaded onto 
a 2% agarose gel containing 6 µl ethidium bromide solution in TRIS-borate-EDTA (TBE) 
buffer. Gel electrophoresis was performed for 15 minutes at 100 V. Afterwards, the gel was 
analyzed using the Gel Doc 2000 system (BioRad Laboratories GmbH, Munich, Germany). 
 
2.7.2 Particle Size and Zeta Potential Measurement 
 
To determine particle size and surface charge, transfection complexes composed of an NP 
ratio of 10 combined with 20 pmol Cy3™ Labeled Pre-miR™ Negative Control #1 and 1 to 6 
μg/ml iron in MNPs were prepared as described above (see 2.6.1.1, 2.6.1.2). MNPs and 
miR/PEI/MNP complexes were diluted in 1 ml glucose solution (5%). The mean 
hydrodynamic diameter was determined by dynamic light scattering (DLS) technique with a 
Brookhaven 90 Plus Nanoparticle Size Analyzer (Brookhaven Instruments Corporation, New 
York, NY, USA). Surface charge was evaluated by a ZetaPALS Analyzer (Brookhaven 
Instruments) using the phase analysis light scattering (PALS) method. 
 
2.8 Transfection Experiments 
 
For experiments in a well plate, appropriate numbers of hMSCs were seeded (Table 4, 5) 24 
hours before transfection of cultured hMSCs or immediately before transfection of freshly 
isolated cells. At the day of transfection, complexes were prepared as described above        
(see 2.6) and added dropwise to the cells. Subsequently, the cells were treated with or without 
the application of a magnetic field using a Super Magnetic Plate (OZ Biosciences) for 20 
minutes. Afterwards, the cells were incubated for 5, 24 or 72 hours at 37 °C and 5% CO2. 
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2.9 Uptake Efficiency and Cytotoxicity 
 
For quantification of uptake efficiency and cytotoxicity, hMSCs were transfected with 
complexes containing Cy3™ dye-Labeled Pre-miR Negative Control #1 as described above 
(see 2.6, 2.8). After transfection, cultured or freshly isolated cells were washed with 1 M 
sodium chloride (NaCl) solution for 5 minutes and centrifuged at 300 g for 10 minutes at       
4 °C. Supernatant was discarded and the cell pellet was resuspended in 100 µl MACS-buffer. 
To evaluate cytotoxicity, the cells were stained with Near-IR LIVE/DEAD
®
 Fixable Dead 
Cell Stain Kit (Life Technologies). Therefor 0.5 µl dye was mixed with the cell suspension 
and incubated for 10 minutes at 4 °C in the dark. Additionally, freshly isolated cells were 
labeled with 10 µl Alexa Fluor 488 mouse anti-human CD105 (clone SN6, AbD Serotec). 
After incubation time, the cells were washed with 1 ml PBS and centrifuged at 300 g for 10 
minutes at 4 °C. The cell pellet was resuspended in 100 µl PBS and fixed with 33 µl PFA 
(4%). 3x10
4
 events were acquired using BD FACS LSRII™ flow cytometer (BD Biosciences) 
and analyzed with BD FACSDiva Software 6 (BD Biosciences). To determine the uptake 
efficiency and cytotoxicity of cultured hMSCs, the number of living Cy3
+
 cells in relation to 
total living cells and the percentage of dead cells in relation to the total cell number were 
calculated, respectively. For freshly isolated cells, the uptake efficiency was evaluated by the 
number of living CD105
+
 Cy3
+
 cells in relation to living CD105
+
 cells. To determine the 
cytotoxicity of transfection complexes, the percentage of dead CD105
+
 cells in relation to 
total CD105
+
 cells was calculated. 
 
2.10 Intracellular Visualization of miR/PEI/MNP Transfection Complexes 
 
2.10.1 Fluorescent Labeling of miR/PEI/MNP Transfection Complexes 
 
Labeling of hsa-miR-335-5p Pre-miR™ miRNA Precursor was performed using LabelIT® 
miRNA Labeling Kit, Version 2 with Cy5™ (Mirus Bio LLC, Madison, USA). According to 
the manufacturer’s protocol, 1 μg miR was mixed with 8 μl Label IT reagent and incubated 
for 2 hours at 37 °C in the dark. Unbound dye was removed using a purification column. 
Labeled miR-Cy5 solution was stored at -20 °C. 
Staining of PEI was carried out using the FluoReporter
®
 Oregon Green
®
 488 Protein Labeling 
Kit (Life Technologies). Therefor 650 μl PEI were mixed with 65 μl sodium bicarbonate 
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solution (1 M). Subsequently, 25 μl Oregon Green® solution (10 mg/mL in DMSO) was 
added to PEI solution and incubated for 1 hour in the dark. For efficient purification of 
unreacted dye, the PEI-488 solution was loaded onto a spin column and centrifuged at 1,100 g 
for 5 minutes. Labeled PEI-488 solution was stored at 4 °C. 
Labeling of MNPs was performed with Atto 565 dye conjugated to biotin during 
miR/PEI/MNP complex formation. Therefor MNPs and Atto 565 at a ratio of 1:1,000 (w/w) 
were mixed with miR/PEI complexes simultaneously. miR/PEI/MNP-565 complexes were 
incubated for 30 minutes in the dark. Labeling of MNPs was freshly performed before each 
transfection. 
Images of labeled complexes were acquired using structured illumination microscopy (SIM) 
mode of an ELYRA PS.1 LSM 780 microscope (Carl Zeiss) with Plan-Apochromat 63x 
objective (1.4 numerical aperture) and analyzed with ZEN 2011 Software (Carl Zeiss). 
 
2.10.2 Confocal Laser Scanning Microscopy 
 
For intracellular visualization of miR/PEI/MNP complexes, 1.5x10
4
 cultured hMSCs were 
seeded on sterilized glass coverslips placed in a 24-well plate with 1 ml MSCGM™ on day 
before transfection. For transfection, labeled miR-Cy5/PEI-488 and miR-Cy5/PEI-488/MNP-
565 complexes composed of an NP ratio of 10 combined with 5 pmol/cm² miR and 1 μg/ml 
iron in MNPs were used. After 72 hours incubation time, the cells were washed with 1 ml 
NaCl solution (1 M) for 1 minute. Then, the cells were fixed with 500 µl PFA solution (4%) 
for 20 minutes at room temperature. After washing with 1 ml PBS, nuclei were stained with 
300 µl DAPI (250 nM) in the dark for 15 minutes at room temperature. Coverslips were 
washed three times with 1 ml PBS on the shaker and were mounted with FluorSave™ on a 
microscope slide. Images were acquired using confocal laser scanning microscopy (LSM) 
mode of an ELYRA PS.1 LSM 780 microscope (Carl Zeiss) with Plan-Apochromat 63x 
objective (1.4 numerical aperture) and analyzed with ZEN 2011 Software (Carl Zeiss). 
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2.11 Real-Time PCR 
 
For real-time polymerase chain reaction (PCR), 1x10
5
 cultured hMSCs per well and 5x10
5
 
freshly isolated hMSCs per well were seeded in a 6-well plate with 4 ml MSCGM™ and a 12-
well plate with 2 ml MSCGM™, respectively. Cells were transfected with miR, miR/PEI or 
miR/PEI/MNP complexes containing hsa-miR-335-5p Pre-miR
TM
 miRNA Precursor (Life 
Technologies) as described above (see 2.6.1.1, 2.6.1.2, 2.8). 
 
2.11.1 RNA Isolation of Cultured hMSCs 
 
Total RNA of cultured hMSCs was isolated using the mirVana™ miRNA Isolation Kit (Life 
Technologies) 5, 24 and 72 hours after transfection according to the manufacturer’s protocol. 
Therefore, medium was removed and attached cells were washed with 1 ml PBS. Then, the 
cells were lysed with 500 μl Lysis/Binding Buffer and detached using a cell scraper (Sarstedt 
AG & Co., Nümbrecht, Germany). 50 μl miRNA Homogenate Additive was added to the 
lysed cells and incubation was performed for 10 minutes on ice. Next, 500 μl acid-phenol 
chloroform was added and the cell lysate was centrifuged at 10,000 g for 5 minutes. The 
upper aqueous phase was transferred into a new tube and mixed with 625 μl ethanol absolute. 
The solution was loaded onto a filter cartridge and centrifuged at 12,000 g for 30 seconds. 
Afterwards, the filter was washed once with 700 μl miRNA wash solution 1 and twice with 
500 μl wash solution 2/3. Then, the filter was centrifuged for drying and transferred into a 
new collection tube. RNA was eluted using 100 μl of 95 °C pre-heated DNase/RNase free 
distilled water. Subsequently, RNA concentration was measured using NanoDrop 1000 
spectrophotometer (Thermo Fisher Scientific). 
 
2.11.2 RNA Isolation of Freshly Isolated hMSCs 
 
Total RNA of fresh hMSCs was isolated using the mirVana™ miRNA Isolation Kit (Life 
Technologies) 72 hours after transfection according to the manufacturer’s protocol. Therefore, 
suspension cells were centrifuged at 300 g for 10 minutes and washed with 1.5 ml PBS. After 
an additional centrifugation step, the cell pellet was resuspended in 500 μl Lysis/Binding 
Buffer. Further RNA isolation was performed as described above (see 2.11.1). 
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2.11.3 Real-Time PCR of miRs 
 
Reverse transcription (RT) of miRs was performed using the TaqMan
®
 MicroRNA Reverse 
Transcription Kit (Life Technologies). First, the RT master mix was prepared according to the 
manufacturer’s instructions (Table 6). Next, 7 µl RT master mix were mixed with 5 µl RNA 
(10 ng) and 3 μl 5x RT primer for hsa-miR-335-5p (Assay ID 000546), hsa-miR-16-5p 
(Assay ID 000391), hsa-miR-191-5p (Assay ID 002299) and RNU6B (Assay ID 001093). 
The mixture was incubated for 5 minutes on ice. RT was performed according to the 
manufacturer’s protocol (Table 7) using a MJ Mini™ Personal Thermal Cycler (BioRad 
Laboratories). 
 
Table 6: Preparation of RT Master Mix for RT of miRs 
 
 
 
 
 
 
 
 
 
 
Table 7: Program for RT of miRs 
Step Time [minutes] Temperature [°C] 
Hold  30 16 
Hold 30 42 
Hold 5 85 
Hold ∞ 4 
 
Real-time PCR was performed using TaqMan
®
 MicroRNA Assays (Life Technologies) for 
human mature miR-335, miR-16, miR-191 and RNU6B. The PCR reaction mix was prepared 
according to the manufacturer’s protocol (Table 8) using TaqMan® 2x Universal PCR Master 
Mix with AmpErase
®
UNG. Afterwards, real-time PCR was performed in a 96-well plate 
Components V [µl] 
100 mM dNTP mix 0.15 
MultiScribe
TM
 Reverse Transcriptase  
(50 U/µl) 
1.00 
10x Reverse Transcription Buffer 1.50 
RNase Inhibitor (20 U/µl) 0.19 
DNase/RNase free distilled water 4.16 
Total volume 7 
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according to the manufacturer’s instructions (Table 9) using the StepOnePlus™ Real-Time 
PCR System (Life Technologies). For each TaqMan
®
 MicroRNA Assay a no template control 
was used. All experiments were performed in triplicates. 
 
Table 8: Real-Time PCR Pipetting Scheme for miR Quantification 
Components V [µl] 
TaqMan
®
 2x Universal PCR Master Mix 
with UNG 
10.00 
nuclease free water 7.67 
20x TaqMan
®
 MicroRNA Assay  1.00 
cDNA product from RT reaction 1.33 
Total volume 20 
 
Table 9: Program for Real-Time PCR 
Step Time [seconds] Temperature [°C] 
Hold 120 50 
Hold 600 95 
40 cycles 
15 95 
60 60 
Hold ∞ 4 
 
To calculate the relative expression ratio (R) the ΔΔCT (threshold cycle) method was used as 
described previously by Livak et al (Equation 2)  [205]. Therefor miR-16, miR-191 and 
RNU6B were used as endogenous normalization controls and untransfected cells served as 
reference. 
 
                                       
 
    (                         )  
 
Equation 2: Calculation of the Relative Expression Ratio (R) using the ΔΔCT Method. 
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2.11.4 Real-Time PCR of Target Genes 
 
RT of target genes was performed using the High Capacity cDNA Reverse Transcription Kit 
with RNase Inhibitor (Life Technologies). At first, 2x RT master mix was prepared according 
to the manufacturer’s protocol (Table 10). Then, 10 µl 2x RT master mix were combined with 
10 µl RNA (400 ng). RT was performed according to the manufacturer’s protocol (Table 11) 
using a MJ Mini™ Personal Thermal Cycler (BioRad Laboratories). 
 
Table 10: Preparation of 2x RT Master Mix for RT of Target Genes 
 
 
 
 
 
 
 
 
 
 
 
Table 11: Program for RT of Target Genes 
Step Time [minutes] Temperature [°C] 
Hold  10 25 
Hold 120 37 
Hold 5 85 
Hold ∞ 4 
 
Real-time PCR was performed using TaqMan
®
 Gene Expression Assays (Life Technologies) 
for TNC (Assay ID Hs01115665_m1), RUNX2 (Assay ID Hs00231692_m1) and Human 
GAPDH as Endogenous Control (Assay ID Hs99999905_m1). The PCR reaction mix was 
prepared according to the manufacturer’s protocol (Table 12). Real-time PCR was performed 
in 96-well plates using the StepOnePlus™ Real-Time PCR System (Life Technologies,   
Table 9). For each TaqMan
®
 Gene Expression Assay a no template control was used. All 
Components V [µl] 
100 mM 25x dNTP mix 0.8 
MultiScribe
™
 Reverse Transcriptase  
(50 U/µl) 
1.0 
10x RT Buffer 2.0 
RNase Inhibitor (20 U/µl) 1.0 
DNase/RNase free distilled water 3.2 
10x RT Random Primers 2.0 
Total volume 10.0 
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experiments were performed in triplicates. To quantify gene expression values of target genes 
the ΔΔCт method was used (Equation 2). Therefor Human GAPD Endogenous Control was 
used as endogenous normalization control for protein coding genes. Untransfected cells were 
used as reference. 
 
Table 12: Real-Time PCR Pipetting Scheme for Target Gene Quantification 
Components V [µl] 
TaqMan
®
 2x Universal PCR Master Mix  
with UNG 
10.0 
nuclease free water 5.0 
20x TaqMan
®
 Gene Expression Assay  1.0 
cDNA product from RT reaction (20 ng) 4.0 
Total volume 20 
 
2.12 Migration Assay 
 
For functional analysis, 4x10
5
 cultured hMSCs per well were seeded in a 24-well plate with 1 
ml MSCGM™ and transfected with miR/PEI/MNP complexes composed of an NP ratio of 10 
combined with 5 pmol/cm² miR (hsa-miR-335-5p Pre-miR™ miRNA Precursor, Pre-miR™ 
miRNA Precursor Molecules - Negative Control #1) and 1 μg/ml iron in MNPs as described 
above (see 2.6.1.2, 2.8). 24 hours after transfection, the cells were washed with 500 μl NaCl 
solution (1 M) for 1 minute and twice with 500 μl PBS for 30 seconds. Afterwards, fresh 
medium was added and a scratch was created using a sterile plastic tip. Live cell imaging was 
performed by sequential acquisition of images every 3 minutes using an ELYRA PS.1 LSM 
780 microscope (Carl Zeiss) for 12 hours at 37 °C and 5% CO2. At the beginning and at the 
end of the experiment, the overgrown surface area was determined with ZEN 2011 Software 
(Carl Zeiss). 
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2.13 Magnetic Targeting of MNPs 
 
For magnetic targeting, MNP solution was vortexed properly and sonicated for 15 minutes. 
Afterwards, one drop of the MNP solution was pipetted onto a coverslip and a neodymium-
iron-boron magnet (1,080–1,120 mT; IBS Magnet, Berlin, Germany) was applied for 10 
minutes. The influence on the MNP behavior in the presence or absence of a magnetic field 
was investigated using an Axiovert 40 CFL microscope (Carl Zeiss). 
 
2.14 In Vitro Magnetic Targeting of hMSCs 
 
For in vitro targeting of cells, 3x10
4
 cultured hMSCs per well and 5x10
5
 freshly isolated 
hMSCs per well were seeded in a 12-well plate with 2 ml MSCGM™. After 24 hours 
incubation time, the cells were transfected with miR/PEI and miR/PEI/MNP complexes 
composed of an NP ratio of 10 combined with 5 pmol/cm² miR (Pre-miR™ miRNA Precursor 
Molecules - Negative Control #1) and 1 μg/ml iron in MNPs as described above (see 2.6.1.2, 
2.8). 24 hours after transfection, the cells were detached with 1 ml trypsin/EDTA and 
centrifuged at 300 g for 10 minutes at 4 °C. The cell pellet was resuspended in 2 ml 
MSCGM™ and seeded in a 12-well plate with or without the application of a neodymium-
iron-boron magnet (1,080–1,120 mT; IBS Magnet). After 4 hours incubation time, images 
were acquired using an Axiovert 40 CFL microscope (Carl Zeiss). 
 
2.15 Statistical Analysis 
 
For all experiments the Student’s t-test was performed using SigmaPlot® 11.0 software 
(Systat Software GmbH, Erkrath, Germany). Relative expression data of CD markers and 
particle size data are shown as mean ± standard deviation (SD). All other values are presented 
as mean ± standard error of the mean (SEM). A p-value < 0.05 was considered to be 
statistically significant. 
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3 Results 
 
3.1 Characterization of Freshly Isolated and Expanded CD105+ hMSCs 
 
3.1.1 Evaluation of Cell Morphology 
 
Bone marrow derived CD105
+
 hMSCs were characterized regarding their cell morphology 
(Figure 4), multilineage differentiation (Figure 5) and surface marker expression (Figure 6) 
before use in further experiments. Immediately after MACS isolation of CD105
+
 cells, freshly 
isolated hMSCs showed a small and rounded morphology comparable to typical suspension 
cells (Figure 4 A). After 20 days under common culture conditions, cells attached to the 
surface of the culture flask thereby increasing in size. Expanded hMSCs formed fibroblast-
like structures with irregularly formed cell extensions (Figure 4 B). 
 
Figure 4: Cell Morphology of Freshly Isolated (A) and Expanded hMSCs (B). Scale bar = 10 µm. 
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3.1.2 Determination of Differentiation Capacity 
 
Subsequently, the differentiation capacity of freshly isolated and cultivated hMSCs was 
investigated (Figure 5). Therefor cells were cultured in adipogenic or osteogenic 
differentiation medium and examined by fluorescent microscopy. Figure 5 demonstrates that 
both freshly isolated and expanded hMSCs were able to differentiate into adipocytes (Figure 5 
A,C) and osteocytes (Figure 5 B,D), respectively. 
 
Figure 5: Differentiation Capacity of hMSCs. Functional differentiation of freshly isolated (A,B) 
and cultured hMSCs (C,D) was shown by immunostaining of FABP-4 (green) for adipocytes (A,C) 
and osteocalcin (red) for osteocytes (B,D) after 20 days under differentiation conditions. Nuclei were 
counterstained with DAPI (blue). Scale bar for adipocytes = 50 µm; Scale bar for osteocytes = 20 µm 
(A is taken from  [206, 207], C and D are taken from  [201, 208]). 
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3.1.3 Evaluation of the hMSC-Immunophenotype 
 
To determine the surface marker expression of hMSCs, freshly isolated and cultured cells 
were analyzed by flow cytometry (Figure 6). Freshly isolated CD105
+ 
cells were highly 
positive for the surface markers CD44 and CD105. They had low expression values of CD29 
and CD45 and no detectable expression of CD73 and CD117 (Figure 6 A,C). In contrast, the 
immunophenotype of cultivated CD105
+
 hMSCs showed high expression of stem cell markers 
CD29, CD44, CD73 and CD105, but the cells were negative for the expression of 
hematopoietic markers CD45 and CD117 (Figure 6 B,C). 
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Figure 6: Immunophenotyping of hMSCs. Immunophenotyping of freshly isolated (A,C) and 
cultured hMSCs (B,C) was investigated by flow cytometry after staining of specific CD surface 
markers. Appropriate isotype controls were used. CD marker expression values are represented as 
mean ± SD; n = 2 (C). (A and C are taken from  [206, 207], B is taken from  [207]). 
 
3.2 Optimization of Transfection Complexes in Cultured hMSCs 
 
3.2.1 Optimization of miR Amounts 
 
In order to optimize transfection efficiencies in cultivated hMSCs, miR/PEI and 
miR/PEI/MNP complexes with different miR amounts (2.5 to 15 pmol/cm² miR) consisting of 
an NP ratio of 10 were tested using flow cytometry (Figure 7). Transfection complexes 
composed of 2.5 pmol/cm² miR showed no significant differences in uptake rates (ranging 
from 27% to 11%) when compared to miR transfection (46%, Figure 7 A). After transfection 
with 5 pmol/cm² miR, miR/PEI and miR/PEI/MNP complexes showed the highest uptake 
rates (ranging from 78% to 71%) and were moderately increased compared to transfection 
with miR alone (62%). Interestingly, a further increase in miR amounts (15 pmol/cm² miR) 
did not lead to further enhancement of uptake rates using miR/PEI and miR/PEI/MNP 
complexes, respectively. 
Additionally, the cytotoxicity of different complex compositions was investigated (Figure 7 
B). miR/PEI and miR/PEI/MNP complexes composed of 2.5 pmol/cm² miR combined with   
1 µg/ml iron in MNPs (~ 11%) showed no cytotoxic effect compared to transfection with miR 
only (9%). Magnetic polyplexes consisting of higher MNP concentrations (2 µg/ml iron in 
MNPs) significantly increased cell mortality about 5% compared to miR transfection. 
Cytotoxicity of transfection complexes with 5 pmol/cm² miR (~ 15%) was moderately 
increased compared to transfection with miR alone (8%). Moreover, cell mortality was further 
enhanced after transfection with miR/PEI and miR/PEI/MNP complexes composed of          
15 pmol/cm² miR reaching highest values under these conditions (~ 25%). Considering the 
highest uptake rates and moderate cell mortality, transfection complexes composed of            
5 pmol/cm² miR were used in further optimization experiments. 
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Figure 7: Transfection Optimization of miR Amounts in Cultured hMSCs. Uptake efficiency (A) 
and cytotoxicity (B) of Cy3™ labeled miR, miR/PEI or miR/PEI/MNP complexes were determined by 
flow cytometry 5 hours post transfection. Transfection complexes were composed of various miR 
amounts (2.5, 5, 15 pmol/cm
2
 miR) combined with an NP ratio of 10 coupled to 1 or 2 µg/ml iron in 
MNPs (MNP 1, MNP 2). Data are represented as mean ± SEM, n = 3, * p ≤ 0.05 vs miR, n.s. = no 
significant difference. (A and B are adopted from  [201, 208]). 
 
3.2.2 Optimization of PEI Amounts 
 
In order to increase transfection performance in expanded hMSCs, miR/PEI complexes with 
different NP ratios were tested using flow cytometry (Figure 8). Therefor the miR amount    
(5 pmol/cm² miR) was kept constant. miR/PEI complexes with low NP ratios (NP ratio 1 to 5) 
resulted in decreased transfection efficiencies (< 20%) compared to miR transfection (~ 48%, 
Figure 8 A). Polyplexes with an NP ratio of 10 (77%) and 33 (70%) showed the highest 
uptake rates. To further enhance the uptake efficiency, a higher NP ratio was investigated. 
However, after transfection with an NP ratio of 50, uptake efficiencies were significantly 
decreased to 2%. 
Moreover, cytotoxicity of the transfection complexes was examined (Figure 8 B). Polyplexes 
with NP ratios from 1 to 10 (ranging from 9% to 18%) showed no significant differences 
compared to transfection with miR only (7%). miR/PEI complexes with an NP ratio of 33 
moderately increased cell mortality (28%) compared to miR transfection. However, an 
increase in the NP ratio (NP ratio 50) led to the highest cytotoxicity value (96%). Thus, with 
respect to highest uptake rates combined with lowest cytotoxicity, polyplexes composed of an 
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NP ratio of 10 and 33 were considered to represent optimal polyplex compositions and were 
utilized in further experiments. Moreover, regarding previous findings with plasmid 
DNA  [202], miR/PEI complexes with an NP ratio of 2.5 were further investigated. 
 
Figure 8: Transfection Optimization of PEI Amounts in Cultured hMSCs. Uptake efficiency (A) 
and cytotoxicity (B) of Cy3™ labeled miR/PEI complexes were evaluated by flow cytometry 5 hours 
after transfection. Polyplexes were composed of various NP ratios (ranging from NP 1 to NP 50) 
combined with 5 pmol/cm² miR. Cells transfected with miR alone were used as control. Data are 
presented as mean ± SEM, * p ≤ 0.05 vs miR, ** p ≤ 0.001 vs miR. For transfection with miR alone 
and polyplexes composed of NP ratios from 1 to 33, experiments were repeated 3 times (n = 3). For 
polyplexes consisting of an NP ratio of 33, the experiment was performed once ($ n = 1) as 
cytotoxicity reached approximately 100% which is in correspondence with previous 
publications  [209, 210]. 
 
3.2.3 Optimization of MNP Amounts 
 
To enhance selectivity of the transfections complexes as well as safety for clinical 
applications, miR/PEI complexes composed of the optimized miR amount (5 pmol/cm² miR) 
and the preselected NP ratios (NP ratio 2.5, NP ratio 10, NP ratio 33) were combined with 
different MNP amounts (from 1 to 6 μg/ml iron in MNPs). Transfection complexes consisting 
of an NP ratio of 2.5 resulted in the lowest uptake efficiencies (~ 1%, Figure 9 A). In contrast, 
miR/PEI and miR/PEI/MNP complexes with an NP ratio of 10 showed the highest uptake 
rates compared to miR transfection (48%). The uptake rates of miR/PEI (76%) and 
miR/PEI/MNP complexes composed of 1 to 2 μg/ml iron in MNPs (ranging from 75% to 
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79%) were significantly enhanced compared to transfection with miR alone. However, 
magnetic polyplexes consisting of higher MNP concentrations (4 and 6 μg/ml iron in MNPs) 
led to a decrease in uptake efficiencies (66% and 62%, respectively) and no significant 
differences compared to miR transfection were observed. The uptake rates at an NP ratio of 
33 were significantly increased after transfection with miR/PEI (71%) and miR/PEI/MNP 
complexes composed of 1 to 4 μg/ml iron in MNPs (ranging from 67% to 70%). However, no 
significant difference was observed after transfection with miR/PEI/MNP complexes 
consisting of 6 μg/ml iron in MNPs (64%) compared to miR transfection.  
Furthermore, cell mortality of different transfection complexes was investigated (Figure 9 B). 
miR/PEI and miR/PEI/MNP complexes composed of an NP ratio of 2.5 (~ 14%) and 10 
(ranging from 16% to 19%) showed no cytotoxic effect when compared to miR transfection 
(7%). However, complexes with an NP ratio of 33 appeared to be toxic for the cells (ranging 
from 24% to 27%). Therefore, with respect to the highest uptake efficiencies accompanied by 
good cell viability, transfection complexes composed of an NP ratio of 10 with 5 pmol/cm² 
miR combined with 1 or 2 µg/ml iron in MNPs were selected as optimal conditions for 
efficient and safe miR delivery in cultured hMSCs. 
 
Figure 9: Transfection Optimization of MNP Amounts in Cultured hMSCs. Uptake efficiency (A) 
and cytotoxicity (B) of Cy3™ labeled miR/PEI and miR/PEI/MNP complexes were investigated by 
flow cytometry after 5 hours incubation time. Transfection complexes were composed of various NP 
ratios (NP 2.5, NP 10, NP 33) combined with 5 pmol/cm² miR coupled to different MNP 
concentrations ranging from 1 to 6 µg/ml iron in MNPs (MNP 1 to MNP 6). miR transfection was 
used as reference. Values are represented as mean ± SEM, n = 3, * p ≤ 0.05 vs miR. (A and B are 
taken from  [201, 208]). 
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3.3 Characterization of Transfection Complexes 
 
3.3.1 Condensation Assay 
 
Condensation of miR by PEI was investigated using gel electrophoresis (Figure 10 A). miR 
without PEI showed a strong and distinct main band which was used as reference. At an NP 
ratio of 0.25 this band disappeared and the complexes migrated slower in the gel. Starting at 
an NP ratio of 0.5, the miR signal in the gel disappeared entirely and miR/PEI complexes 
remained in the slots. 
 
3.3.2 Determination of Particle Size and Zeta Potential 
 
MNPs, miR/PEI and miR/PEI/MNP complexes were characterized regarding their surface 
charge using PALS (Figure 10 B). MNPs alone were negatively charged (-17.0 mV). In 
contrast, miR/PEI complexes had a strong positive surface charge (+41.6 mV). The surface 
charge of miR/PEI/MNP complexes composed of 1 µg/ml iron in MNPs was slightly 
decreased to +32.8mV compared to polyplexes alone. However, magnetic polyplexes with 
higher MNP amounts (from 2 to 6 µg/ml iron in MNPs) had significantly decreased surface 
charges (ranging from +15.6 to +7.7 mV) compared to miR/PEI complexes. 
Particle size of MNPs, miR/PEI and miR/PEI/MNP complexes was determined by DLS 
(Figure 10 C). Both, MNPs and miR/PEI complexes had effective diameters around 100 nm. 
Moreover, particle size of miR/PEI/MNP complexes with 1 to 6 µg/ml iron in MNPs was 
increased and ranged between 150 to 200 nm. 
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Figure 10: Classification of Transfection Complexes. (A) Condensation behavior of miR by PEI 
was investigated using gel electrophoresis. Polyplexes were composed of several NP ratios (ranging 
from NP 0.1 to NP 33) and 20 pmol miR. The miR band served as positive control. (B,C) Zeta 
potential (B) and particle size (C) of MNPs, miR/PEI and miR/PEI/MNP complexes were evaluated 
by PALS and DLS. Transfection complexes were composed of an NP ratio of 10 combined with       
20 pmol miR coupled to various MNP concentrations ranging from 1 to 6 μg/ml iron in MNPs (MNP 
1 to MNP 6). Zeta potential values are represented as mean ± SEM, n = 10. Particle size data are 
shown as mean ± SD, n = 10. (A, B and C are taken from  [201], A is taken from  [208]). 
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3.4 Evaluation of miR Processing in Cultured hMSCs over Time 
 
3.4.1 Investigation of Mature miR Expression Levels 
 
Cultivated hMSCs were transfected with miR, miR/PEI and miR/PEI/MNP complexes and 
the expression level of mature miR-335 was quantified by real-time PCR (Figure 11). 
Initially, different potential endogenous normalization controls were tested 5 hours after 
transfection (Figure 11 A). Results indicated no significant differences in miR-335 levels 
when miR-16, miR191 or RNU-6B were used as internal normalization controls. 
Moreover, the processing of pre-miR into mature miR-335 was monitored 5, 24 and 72 hours 
post transfection, respectively (Figure 11 B). 5 hours after transfection, the level of miR-335 
was increased about 10-fold after transfection with miR only. A significant increase of miR-
335 levels (about 10-fold) was observed after transfection with miR/PEI or miR/PEI/MNP 
complexes compared to miR only transfection. Furthermore, in the latter case the miR-335 
expression level was decreased, equaling that of untransfected cells after 24 hours. Moreover, 
cells transfected with miR/PEI and miR/PEI/MNP complexes reached highest values and 
showed a more than 1,000-fold enhancement compared to cells treated with miR alone. After 
72 hours incubation time, miR-335 expression remained at a constant level after transfection 
with miR/PEI/MNP complexes. However, after transfection with miR/PEI complexes, miR-
335 values were decreased about 3-fold compared to MNP-mediated transfection. 
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Figure 11: Monitoring of pre-miR-335 Processing in Cultured hMSCs. (A) hMSCs were 
transfected with optimized transfection complexes and the level of the mature miR-335 strand was 
detected by real-time PCR 5 hours after transfection with respect to different endogenous 
normalization controls (miR-16, miR-191, RNU-6B). (B) Processing of pre-miR-335 into mature miR-
335 after transfection with miR/PEI or miR/PEI/MNP complexes was examined by real-time PCR 
after 5, 24 and 72 hours incubation time. hMSCs transfected with miR alone served as control. The 
miR-335 expression level in untransfected cells is indicated by a dashed line. Right plot demonstrates 
a linear representation of the relative miR-335 expression 72 hours after transfection. RNU-6B was 
used as normalization control. Data are represented as mean ± SEM, n = 5, ** p ≤ 0.001 vs miR,       
## p ≤ 0.001 vs PEI-mediated transfection, n.s. = no significant difference. (B is taken from  [201]). 
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3.4.2 Microscopic Observations of Transfection Complexes 
 
Initially, the quality of 3-color labeling of miR/PEI/MNP complexes was investigated using 
SIM (Figure 12). After investigating the single channels, visual co-localization of miR 
together with PEI and MNPs was observed. 
 
Figure 12: Visualization of Transfection Complexes. miR/PEI/MNP complexes were fluorescently 
labeled and visualized using SIM. Staining of miR-335 was performed using Cy5™ dye (cyan). PEI 
was labeled with Oregon Green
®
 488 (yellow) and MNP staining was done with Atto 565 (red). Scale 
bar = 0.25 µm. 
 
Furthermore, labeled miR/PEI/MNP complexes were visualized inside the cell 72 hours post 
transfection using confocal LSM and were compared to PEI-mediated transfection. Figure   
13 A demonstrates that condensed miR/PEI complexes were distributed inside the cytoplasm 
but also inside the nucleus. In contrast, magnetic polyplexes were randomly distributed 
exclusively in the cytoplasm but did not enter the nucleus (Figure 13 B). 
 3 Results 52 
 
 
 
 
Figure 13: Intracellular Visualization of Transfection Complexes in Cultured hMSCs. hMSCs 
were transfected with fluorescently labeled miR/PEI (A) or miR/PEI/MNP complexes (B) and 
observed by confocal LSM 72 hours after transfection. miR-335 staining was performed with Cy5™ 
dye (cyan). PEI was labeled with Oregon Green
®
 488 (yellow). MNPs were stained with Atto 565 
(red). Nuclei were counterstained with DAPI (gray). The arrows show condensed polyplexes inside 
the nucleus. Scale bar = 5 μm. (A and B are taken from  [201]). 
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3.4.3 Evaluation of Target Genes Expression 
 
Expanded hMSCs were transfected with miR, miR/PEI or miR/PEI/MNP complexes and the 
expression levels of miR-335 target genes TNC and RUNX2 were detected 5, 24 and 72 hours 
post transfection by real-time PCR (Figure 14). Transfection with miR-335 alone did not lead 
to an efficient knockdown of the investigated target genes compared to untransfected cells 
over time. However, 24 hours after transfection with both miR/PEI and miR/PEI/MNP 
complexes, a significant knockdown of TNC (65% vs 61%) and RUNX2 (56% vs 60%) was 
observed when compared to control. 72 hours after polyplex transfection, the expression of 
TNC remained at the same level, while the RUNX2 expression level rose to 62%. In contrast, 
after MNP-mediated transfection the mRNA levels of TNC and RUNX2 were further down-
regulated to 41% and 52%, respectively, compared to untransfected cells and were 
significantly reduced compared to PEI-mediated transfection. 
 
Figure 14: Gene Knockdown of TNC and RUNX2 after miR-335 Transfection in Cultured 
hMSCs. After transfection with optimized transfection complexes, relative gene expression of TNC 
(A) and RUNX2 (B) was determined by real-time PCR 5, 24 and 72 hours after transfection. miR 
transfection was used as control. The miR-335 expression level in untransfected cells is indicated by a 
dashed line. GAPDH served as endogenous normalization control. Values are represented as mean ± 
SEM, n = 5, * p ≤ 0.05 vs miR, ** p ≤ 0.001 vs miR, ## p ≤ 0.001 vs PEI-mediated transfection.       
(A and B are taken from  [201]). 
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3.4.4 Analysis of Migratory Potential 
 
Cultured hMSCs were transfected with miR/PEI/MNP complexes and their migratory 
behavior was investigated 24 hours after miR-335 transfection using live cell imaging   
(Figure 15). MNP-containing complexes composed of scrambled miR (53.5%) had no 
influence on cell migration compared to control (57.2%). However, after transfection with 
miR/PEI/MNP complexes consisting of functional miR-335, the migratory ability of hMSCs 
(25.7%) was significantly reduced compared to untransfected cells. 
 
 
Figure 15: Inhibition of the Migratory Ability of Cultured hMSCs after miR-335 Transfection. 
(A) 24 hours after transfection with optimized miR/PEI/MNP complexes, migratory behavior of 
cultured hMSCs was tested over a period of 12 hours using live cell imaging. Untransfected cells 
served as control. Data are shown as mean ± SEM, n = 5, ** p ≤ 0.001. (B,C) Expanded hMSCs were 
transfected with magnetic polyplexes consisting of scrambled miR (B,B‘) or miR-335 (C,C‘). Directly 
after (B,C) and 12 hours after scratching (B‘,C‘), images were taken. Values reflect the free surface 
area. Scale bar = 200 μm. (A,B and C are taken from  [201]). 
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3.5 Optimization of Transfection Complexes in Freshly Isolated hMSCs 
 
3.5.1 Optimization of miR Amount 
 
In order to optimize transfection efficiencies in freshly isolated hMSCs, miR/PEI complexes 
with different miR amounts (2.5 to 15 pmol/cm² miR) at an NP ratio of 10 were tested using 
flow cytometry (Figure 16). Transfection with polyplexes consisting of 2.5 pmol/cm² miR 
resulted in the lowest uptake rates (1%, Figure 16 C). miR/PEI complexes composed of          
5 pmol/cm² miR led to the highest uptake efficiencies (58%) which were significantly 
enhanced compared to miR transfection alone (37%). Moreover, an increase in miR amounts 
(10 and 15 pmol/cm² miR) showed a stepwise enhancement of uptake rates (38% vs 62%). 
However, after PEI-mediated transfection, uptake efficiencies were reduced to 20% and 8%, 
respectively. 
Additionally, potential cytotoxicity of polyplexes was examined (Figure 16 D). Thereby, 
untransfected cells served as control (23%) reflecting toxicity of the isolation process. 
Transfection complexes composed of 2.5 pmol/cm² miR (28% after miR transfection, 22% 
after PEI-mediated transfection) showed no cytotoxic effect when compared to control. 
Moreover, cytotoxicity of miR/PEI complexes consisting of 5 and 10 pmol/cm² miR (~ 47%), 
respectively, was increased compared to transfection with miR alone (22% vs 26%). 
However, polyplexes and miR transfection with 15 pmol/cm² miR showed the highest values 
(78% vs 56%) and were significantly increased compared to control. With respect to the 
highest uptake rates and lowest cytotoxicity, 5 and 10 pmol/cm² miR were selected and 
utilized in further experiments. 
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Figure 16: Transfection Optimization of miR Amounts in Freshly Isolated hMSCs. (A,B) Gating 
strategy to determine the uptake efficiency. (A) Untreated living CD105
+
 cells served as negative 
control. (B) hMSCs were transfected with Cy3™ labeled transfection complexes and the number of 
living CD105
+
 Cy3
+
 cells in relation to living CD105
+
 cells was determined. (C,D) Uptake efficiency 
(C) and cytotoxicity (D) of Cy3™ labeled miR and miR/PEI complexes were determined by flow 
cytometry 24 hours after transfection. Transfection complexes were composed of an NP ratio of 10 
combined with various miR amounts (2.5, 5, 10 and 15 pmol/cm
2
 miR). Untransfected cells were used 
as control. Data are represented as mean ± SEM, n = 3, * p ≤ 0.05 vs miR, # p ≤ 0.05 vs control.       
(A and B
 
are taken from  [206, 207]). 
 
  
* 
* * 
# 
# 
# 
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3.5.2 Optimization of PEI Amount 
 
To further improve transfection performance in freshly isolated hMSCs, miR/PEI complexes 
with different NP ratios (NP ratio 2.5, NP ratio 10, NP ratio 33) and two selected miR 
amounts (5 pmol/cm² miR, 10 pmol/cm² miR) were investigated by flow cytometry      
(Figure 17). Polyplexes composed of 5 pmol/cm² miR with an NP ratio of 2.5 resulted in 
moderate uptake rates (32%, Figure 17 A). To further enhance uptake efficiency, higher NP 
ratios (NP ratio 10, NP ratio 33) were tested. PEI-mediated transfection using an NP ratio of 
10 showed the highest uptake efficiencies (56%). However, PEI-based transfection with an 
NP ratio of 33 significantly decreased the uptake rates (1%). Moreover, miR/PEI complexes 
composed of 10pmol/cm² miR were investigated. The best uptake rates were achieved using 
transfection complexes composed of an NP ratio of 2.5 (69%). Nevertheless, an increase in 
NP ratios (NP ratio 10, NP ratio 33) led to a significant decrease in uptake efficiencies     
(12% vs 2%). 
Furthermore, cytotoxicity of polyplex transfection was investigated (Figure 17 B). Therefor 
untransfected cells were used as control (29%). miR/PEI complexes composed of an NP ratio 
of 2.5 (35% vs 32%) showed no significant differences compared to control. Moreover, 
transfection complexes composed of an NP ratio of 10 and 5 pmol/cm² miR (46%) moderately 
increased cell mortality. However, transfection complexes composed of an NP ratio of 10 and 
10 pmol/cm² miR (67%) showed the highest cytotoxicity levels. Likewise, an increase in the 
NP ratio (NP ratio 33) led to high cytotoxicity values after PEI-mediated transfection with 
5pmol/cm² miR (57%) and with 10 pmol/cm² miR (55%), respectively. Therefore, regarding 
the highest uptake rates and lowest cytotoxicity, miR/PEI complexes composed of an NP ratio 
of 10 combined with 5 pmol/cm² miR and transfection complexes with an NP ratio of 2.5 
combined with 10 pmol/cm² miR were selected and used in further experiments. 
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Figure 17: Transfection Optimization of PEI Amounts in Freshly Isolated hMSCs. Uptake 
efficiency (A) and cytotoxicity (B) of Cy3™ labeled miR/PEI complexes were investigated by flow 
cytometry 24 hours after transfection. Polyplexes were composed of various NP ratios (NP 2.5, NP 10, 
NP 33) combined with 5 or 10 pmol/cm² miR. Untransfected cells served as control. Data are 
represented as mean ± SEM, n = 3, * p ≤ 0.05. (A and B are adopted from  [206, 207]). 
 
3.5.3 Optimization of MNP Amount 
 
In order to increase the specificity of our transfection system, different MNP amounts (1 or 2 
μg/ml iron in MNPs) were combined with the two optimized miR/PEI complex variants. A 
potential influence of different complex compositions on uptake efficiency (Figure 18 A,C) 
and cytotoxicity (Figure 18 B,D) with or without the application of a magnetic field was 
investigated by flow cytometry. Uptake rates of miR/PEI/MNP complexes composed of an 
NP ratio of 10 combined with 5 pmol/cm² miR showed no significant differences (ranging 
from 62% to 76%) compared to miR/PEI complexes (81%) in the absence of a magnetic field 
(Figure 18 A). Moreover, cytotoxicity of these complexes showed no cytotoxic effect (24% vs 
27%) when compared to miR/PEI complexes (30%) and control (20%, Figure 18 B), 
respectively. 
Similarly, miR/PEI complexes consisting of an NP ratio of 2.5 combined with 10 pmol/cm² 
miR coupled to 1 or 2 µg/ml iron in MNPs were tested. Uptake rates of MNP-mediated 
transfection (ranging from 57% to 65%) did not lead to significant differences compared to 
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corresponding miR/PEI complexes (77%) without the application of a magnetic field    
(Figure 18 C). Additionally, similar values of cytotoxicity were observed for transfected cells 
(ranging from 15% to 18%) and untransfected controls (17%, Figure 18 D). Moreover, a 
magnetic field was applied and the influence on uptake efficiency and cytotoxicity was 
examined. However, no significant differences were observed in the presence of an external 
magnetic field. In the following experiments, miR/PEI/MNP complexes composed of an NP 
ratio of 10 combined with 5 pmol/cm² miR coupled to 1 μg/ml iron in MNPs and magnetic 
complexes consisting of an NP ratio of 2.5 combined with 10 pmol/cm² miR bound to 1 μg/ml 
iron in MNPs were used. 
 
Figure 18: Transfection Optimization of MNP Amounts in Freshly Isolated hMSCs with (+ M) 
and without (- M) the Application of a Magnetic Field. Uptake efficiency (A,C) and cytotoxicity 
(B,D) of Cy3™ labeled miR/PEI and miR/PEI/MNP complexes were investigated by flow cytometry 
after 24 hours incubation time. Polyplexes were composed either of an NP ratio of 10 combined with  
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5 pmol/cm² miR (A,B) or of an NP ratio of 2.5 combined with 10 pmol/cm² miR (C,D). Furthermore, 
miR/PEI complexes could be bound to 1 or 2 µg/ml iron in MNPs (MNP 1, MNP 2). Values are 
represented as mean ± SEM, n = 3, n.s. = no significant difference. (A, B, C and D are taken 
from  [206, 207]). 
 
3.6 Evaluation of miR Processing in Freshly Isolated hMSCs 
 
In order to differentiate between the transfection performances of the two optimized magnetic 
complexes, the expression levels of mature miR-335 in freshly isolated hMSC were quantified 
by real-time PCR 72 hours post transfection (Figure 19). After transfection with 
miR/PEI/MNP complexes consisting of an NP ratio of 10 combined with 5 pmol/cm² miR 
coupled to 1 μg/ml iron in MNPs, miR-335 expression levels were increased about 70-fold 
compared to untransfected cells. Moreover, transfection complexes composed of an NP ratio 
of 2.5 combined with 10 pmol/cm² miR bound to 1 μg/ml iron in MNPs further enhanced the 
miR-335 levels about 220-fold as compared to untreated controls. However, no significant 
differences between the investigated magnetic polyplexes were observed. 
 
Figure 19: Processing of pre-miR-335 in Freshly Isolated hMSCs. hMSCs were transfected with 
the two optimized miR/PEI/MNP complexes (composed of 5 pmol/cm² miR with an NP ratio of 10 
bound to 1 µg/ml iron in MNPs (MNP 1) or 10 pmol/cm² miR with an NP ratio of 2.5 bound to 1 
µg/ml iron in MNPs (MNP 1)) and the level of the mature miR-335 strand was detected by real-time 
PCR 72 hours after transfection. The dashed line shows the miR-335 expression level in untreated 
cells. RNU-6B was used as endogenous normalization control. Data are represented as mean ± SEM,  
n = 3, n.s. = no significant difference. 
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3.7 Evaluation of MNP-mediated Transfection in Comparison to Established 
Magnetic Transfection Reagents in Freshly Isolated hMSCs 
 
Uptake efficiency (Figure 20 A,C) and cytotoxicity (Figure 20 B,D) of optimized magnetic 
polyplexes were compared to commercially available magnetic carrier systems (CombiMag 
particles and Magnetofectamine
®
) using flow cytometry. Transfection with miR/PEI/MNP 
complexes composed of an NP ratio of 10 combined with 5 pmol/cm² miR bound to 1 μg/ml 
iron in MNPs resulted in high uptake rates of about 68% (Figure 20 A). Furthermore, uptake 
efficiencies of miR/PEI/CombiMag (64%) and miR/Magnetofectamine
®
 (59%) complexes 
were comparable to those of MNP-mediated transfection. Moreover, no significant 
differences in cell mortality between transfected and control cells were observed (ranged from 
11% to 17%, Figure 20 B). 
Likewise, uptake efficiency (Figure 20 C) and cytotoxicity (Figure 20 D) of miR/PEI/MNP 
complexes composed of an NP ratio of 2.5 combined with 10 pmol/cm² miR bound to 1 μg/ml 
iron in MNPs were tested. Highest uptake rates (79%) were obtained after transfection with 
miR/PEI/MNP complexes. Moreover, miR/PEI/CombiMag (56%) and 
miR/Magnetofectamine
®
 (75%) reached similar uptake levels. Besides, cell mortality values 
of transfected (ranging from 9% to 14%) and control cells were not significantly different. 
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Figure 20: Transfection Performances of Optimized miR/PEI/MNP Complexes in Comparison 
with Commercially Available Magnetic Transfection Carriers in Freshly Isolated hMSCs. 
Uptake efficiency (A,C) and cytotoxicity (B,D) of Cy3™ labeled miR/PEI/MNP, miR/PEI/CombiMag 
and miR/Magnetofectamine
®
 complexes were investigated by flow cytometry 24 hours after 
transfection in the presence of a magnetic field. miR/PEI/MNP complexes were composed either of an 
NP ratio of 10 combined with 5 pmol/cm² miR coupled to 1 µg/ml iron in MNPs (MNP 1; A,B) or of 
an NP ratio of 2.5 combined with 10 pmol/cm² miR bound to 1 µg/ml iron in MNPs (MNP 1; C,D). 
For the preparation of commercially available magnetic transfection complexes, corresponding 
amounts of Lipofectamine
®
 2000 and CombiMag particles were used. Untreated cells were used as 
control. Values are presented as mean ± SEM, n = 3, n.s. = no significant difference. (A, B, C and D 
are taken from  [206, 207]). 
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3.8 In Vitro Magnetic Targeting of hMSCs 
 
Initially, paramagnetic properties of the filtered MNP suspension were investigated using 
transmitted light microscopy. In the absence of a magnetic field, MNPs were properly 
dispersed in solution and did not perform any targeted movements (Figure 21 A). However, 
with the application of a magnetic field, MNPs started to move directly towards the magnet 
(Figure 21 B). After removing the magnet, MNPs stopped their directed movement and were 
evenly dispersed (Figure 21 C). 
 
Figure 21: Paramagnetic Properties of MNPs. (A-C) The paramagnetic properties of MNPs were 
analyzed by transmitted light microscopy with (+ M) or without the application of a magnetic field     
(- M). Scale bar = 10 µm. 
Furthermore, hMSCs were transfected with optimized miR/PEI and miR/PEI/MNP complexes 
composed of an NP ratio of 10 combined with 5 pmol/cm² miR bound to 1 μg/ml iron in 
MNPs and the effect of magnetic targeting was determined using transmitted light microscopy 
(Figure 22 A,B). Untransfected cells were used as control (Figure 22 C). After transfection 
with magnetic polyplexes, cultured hMSCs could be targeted by an external magnetic field 
(Figure 22 A). The majority of the cells accumulated in the area of the magnet. However, few 
hMSCs were randomly distributed at the border zone, where no magnetic field was applied. 
On the contrary, hMSCs transfected with miR/PEI/MNP complexes without the application of 
a magnet (Figure 22 A‘) were equally distributed in the whole well. After polyplex 
transfection, no specific targeting of hMSCs was observed in the presence (Figure 22 B) or 
absence (Figure 22 B‘) of a magnetic field and the distribution of cells were comparable to 
untranfected cells (Figure 22 C,C‘). Moreover, targeting experiments using freshly isolated 
cells showed comparable results (data not shown). 
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Figure 22: In Vitro Magnetic Targeting of Cultured hMSCs. 24 hours after transfection with 
optimized miR/PEI/MNP (A, A‘) and miR/PEI complexes (B, B‘), magnetic targeting of cultured 
hMSCs in the presence (A, B, C) or absence of a magnetic field (A‘, B‘, C‘) was tested using 
transmitted light microscopy. Untransfected cells were used as control (C, C‘). Scale bar = 10 µm. 
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4 Discussion 
 
4.1 Comparison of Freshly Isolated and Expanded CD105+ hMSCs 
 
CVDs are the leading cause of death worldwide  [59]. Beside conventional therapies, cell-
based approaches gained huge attention for regeneration of the injured heart during the last 
years. Cell-based therapies have the potential to replace damaged cardiac tissue and improve 
heart function after myocardial infarction with the aim to avoid heart transplantation. In recent 
years, bone marrow derived hMSCs have shown great therapeutic potential in treatment of 
CVDs  [211]. Their protective function has been explained by different mechanisms, e.g. by 
secretion of anti-apoptotic, angiogenic, anti-inflammatory or matrix-mediating factors as well 
as by differentiation into various cell types  [51, 212]. In general, MSCs are characterized by 
their expression of specific surface markers (e.g. CD29, CD44, CD73, CD105) as well as by 
their multilineage differentiation capacity  [22]. In this work, hMSCs were isolated using anti-
CD105 antibodies as it was shown, that CD105 is a suitable antigen for effective hMSCs 
purification  [28]. Moreover, our group has demonstrated that CD105 purified and expanded 
hMSCs showed better cell survival in the infarcted heart and an improved effect on cardiac 
regeneration  [204]. However, in vitro expanded MSCs were shown to develop altered gene 
expression patterns, loss of the C-X-C chemokine receptor type 4 (CXCR4) which is 
important for stem cell homing in vivo and a loss of their differentiation potential  [213, 214, 
215]. Furthermore, cell expansion is a time consuming and potentially harmful process  [35]. 
Therefore, freshly isolated cells might be preferable for clinical applications. While the low 
cell number seems to limit the use of uncultured primary cells, Wise et al could demonstrate 
similar differentiation performances for freshly isolated MSCs as well as for expanded cells, 
even though the number of uncultured MSCs was by far smaller  [216]. In our studies, 
immunophenotyping of freshly isolated CD105
+
 cells was compared to expanded hMSCs 
(Figure 6). Our results showed a slightly different surface marker expression pattern of 
uncultured cells when compared to expanded hMSCs. While CD44, CD105 and CD117 are 
equally expressed in both freshly isolated and cultured hMSCs, the expression of CD45 was 
altered. Previously, it was shown that freshly isolated CD105
+
 cells moderately expressed 
CD45 which was down-regulated during culture expansion  [28]. Moreover, CD29 was 
weakly expressed on the surface of freshly isolated CD105
+
 cells, while after culture all cells 
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were positive for CD29. CD29 is a membrane receptor involved in cell adhesion  [217]. 
Therefore, it might be upregulated during cell expansion as hMSCs become adherent over 
time. Furthermore, in freshly isolated hMSCs CD73 surface expression was significantly 
decreased when compared to expanded cells which is in line with previous findings by Boiret 
et al  [213]. Equally to our study, Aslan et al investigated bone marrow derived freshly 
isolated CD105
+
 cells. Interestingly, though freshly isolated CD105
+
 cells showed a different 
immunophenotype compared to expanded cells, they could demonstrate that uncultured cells 
were able to develop all typical properties of hMSCs after expansion  [28]. Moreover, in our 
experiments freshly isolated hMSCs were able to be plastic adherent and showed a typical 
spindle-shaped morphology after 20 days in cell culture (Figure 4) as it is required by the 
International Society for Cellular Therapy  [22]. To confirm the stem cell character of freshly 
isolated hMSCs, cells were characterized by their multilineage differentiation. It was shown, 
that freshly isolated hMSCs were able to differentiate into adipocytes and osteocytes similar 
to expanded hMSCs (Figure 5), which is in agreement with previous publications  [45, 218, 
219]. 
 
4.2 Establishment of a Standardized miR Transfection Protocol in Expanded 
hMSCs 
 
Beside the beneficial properties of hMSCs, their clinical applications are restricted, e.g. due to 
poor cell viability after transplantation into the heart  [61]. Therefore, the therapeutic potential 
of hMSCs in cardiac regeneration can be improved by genetic modifications using specific 
miRs  [135, 136, 137]. Recently, our group developed a magnetic non-viral vector system 
consisting of biotinylated PEI bound to streptavidin coated MNPs for DNA delivery (up to 
10%) in cultivated hMSCs  [220]. Therefore, we aimed to transfer this non-viral approach for 
miR delivery to hMSCs. Initially, we performed transfection optimization experiments in 
cultured hMSCs due to the high cell number that is required. Uptake efficiency and 
cytotoxicity of different complex formulations were investigated 5 hours after transfection. At 
this time point, it was shown that magnetic iron oxide containing PEI nanospheres were 
attached to the cell membrane and internalized inside the cell via endocytosis  [221]. 
Moreover, we intended to avoid paracrine secretion of transfection complexes within 
microvesicles towards adjacent cells. Silva et al showed that under stress, MSCs released iron 
oxide nanoparticles throughout the organism where they can be taken up by host cells  [222]. 
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Thus, it would lead to misinterpretation of our uptake efficiency data. At first, hMSCs were 
transfected with miR alone, miR/PEI or magnetic miR/PEI/MNP complexes using different 
miR amounts (2.5 to 15 pmol/cm² miR) at an NP ratio of 10 (Figure 7). In all optimization 
experiments, negative control miR was used which has no function inside the cell. Thus, the 
observed effects on uptake efficiency and cell viability can be correlated to the different 
complex compositions. Interestingly, the uptake rates after transfection of expanded hMSCs 
with miR alone were relatively high (between 45% and 85%). However, Urban-Klein et al 
demonstrated that more than 90% of unprotected siRNA was degraded already after 15 
minutes. In contrast, PEI complexes efficiently protected siRNA against enzymatic 
degradation and released bioactive siRNA inside the cell  [172]. Additionally, systemic 
administration of naked siRNA in vivo was shown to have no therapeutically relevant 
effect  [223]. As miR and siRNA have comparable structure, size and intracellular 
functionality, siRNA results can be transferred as a basis for miR delivery. Moreover, 
miR/PEI and miR/PEI/MNP complexes composed of 5 pmol/cm² miR transfected highly 
efficient around 75% cultured hMSCs with low cytotoxic effect (~ 15%). Although in 
previous studies higher amounts of small RNAs were used  [178, 224, 225], in our 
experiments it did not further enhance uptake efficiency. However, a higher miR amount    
(15 pmol/cm² miR) increased cytotoxicity (~ 25%). Scholz et al stated that for successful 
siRNA delivery, a high cargo loading is required  [157]. Therefore, regarding the highest 
uptake rates und the lowest cytotoxicity, transfection complexes composed of 5 pmol/cm² 
miR were used in the following experiments. 
To further optimize transfection in expanded hMSCs, PEI polyplexes with different NP ratios 
(NP ratio 1 to NP ratio 50) and 5 pmol/cm² miR were tested (Figure 8). Previously it was 
demonstrated, that distinct NP ratios were remarkably influencing uptake efficiency of 
transfection complexes - thus we selected a broad range from NP ratio 1 to NP ratio 50  [226]. 
Moreover, in recent publications it was shown that PEI can deliver siRNA both in vitro and in 
vivo  [172, 227, 228]. Although in former studies for DNA delivery NP ratios of 2.5 and 5 
showed the highest transfection efficiencies  [220], in our experiments miR/PEI complexes 
composed of low NP ratios (NP ratio 1, NP ratio 2.5, NP ratio 5) did not improve uptake 
rates. Moreover, Grayson et al could demonstrate that NP ratios higher than 6 have to be used 
for successful siRNA delivery  [178]. hMSC transfection using polyplexes with an NP ratio of 
10 or 33 showed the highest uptake rates (70% to 80%) which is in agreement with previous 
studies for PEI-mediated siRNA delivery  [172, 176, 224, 229]. However, a further increase 
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of the PEI concentration (NP ratio 50) dramatically decreased the uptake efficiency due to the 
highest cytotoxicity of approximately 100%. It is known, that higher NP ratios resulted in 
increased cytotoxicity due to the higher PEI amount that is used to form complexes  [230]. In 
previous studies it was demonstrated, that PEI can cause toxicity by randomly binding various 
negatively charged nuclear components and destructing membrane integrity, thus interfering 
with critical cell functions and inducing apoptosis  [231, 232]. Moreover, it was shown that an 
NP ratio of 50 was correlated with high cytotoxicity in a human embryonal kidney cell line 
and a rat liver cell line  [209, 210]. Thus, PEI polyplexes composed of an NP ratio of 50 were 
tested just once (n=1). Regarding the highest uptake efficiencies, polyplexes with an NP ratio 
of 10 and 33 as well as polyplexes with an NP ratio of 2.5 which performed best in 
combination with MNP for DNA transfection in expanded hMSCs were selected for 
additional transfection experiments  [220]. 
To improve the selectivity of the transfection vector, preselected polyplexes were coupled to 
MNPs (ranging from 1 to 6 µg/ml iron in MNPs) to enable specific magnetic targeting. 
Previously, it was shown by our group, that MNP-based complexes significantly enhanced 
DNA transfection in hMSCs even without the application of a magnetic field which was 
explained by different transfection mechanisms of DNA/PEI and DNA/PEI/MNP 
complexes  [202]. Therefore, in the following experiments no magnetic field was preliminary 
applied. We could demonstrate that transfection complexes composed of an NP ratio of 2.5 
resulted in the lowest uptake rates (~ 1%, Figure 9). Although, an NP ratio of 2.5 performed 
well in DNA transfection of COS7 cells  [220], for miR delivery it was not suitable which 
could be explained by different structure, function and stability of miR when compared to 
DNA  [157, 228]. Additionally, it was shown that for condensation of siRNAs higher PEI 
concentrations were needed due to the lower charge density and higher stiffness when 
compared to DNA  [233]. Moreover, miR/PEI and miR/PEI/MNP complexes composed of an 
NP ratio of 33 significantly increased cytotoxicity by about 20% when compared to 
transfection using miR alone. In line with our findings, Kwok et al demonstrated that NP 
ratios higher than 20 significantly increased cytotoxicity. They explained this effect by the 
excess of free PEI within the transfection solution  [228]. Interestingly, magnetic polyplexes 
composed of an NP ratio of 10 showed highest uptake rates at low MNP dosage (1 to 2 μg/ml 
iron in MNPs) when compared to control (75% vs 50%) without cytotoxic effects. It is 
known, that higher MNP concentrations are correlated with higher transfection rates  [234]. 
However, in our experiments an increase in MNP amounts (4 to 6 μg/ml iron in MNPs) did 
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not lead to a further enhancement of uptake rates. Thus, magnetic polyplexes composed of 4 
to 6 μg/ml iron in MNPs were not used in further experiments as they did not show any 
beneficial effects for successful hMSC transfection. In the following investigations, magnetic 
complexes containing 1 to 2 μg/ml iron in MNPs were used. Moreover, miR/PEI and 
miR/PEI/MNP complexes (1 to 2 µg/ml iron in MNPs) showed similar performances 
regarding their uptake efficiencies which might indicate maximal transfection values possible 
in hMSCs. Therefore, uptake rates cannot be further enhanced by MNPs. However, magnetic 
complexes can by targeted by an external magnetic field and monitored via MRI which may 
become important for future in vivo applications  [200, 235]. Additionally, magnetic targeting 
can enhance transfection efficiency and safety which is necessary for clinical applications as 
well as reduce cytotoxicity, dosage and costs  [236]. Moreover, it was shown that MNP 
transfected cells could be guided by an externally applied magnet  [183, 191]. Cheng et al 
demonstrated that cardiosphere derived cells transfected with iron oxide MNPs improved cell 
engraftment and cardiac function after myocardial infarction  [237]. Thus, MNP-mediated 
stem cell targeting offers new perspectives for heart regeneration. 
 
4.3 Physicochemical Characterization of Transfection Complexes 
 
The physicochemical properties of the transfection vector are important factors influencing 
miR delivery and release inside the cell. An essential requirement for successful miR-
mediated transfection is the ability to form stable complexes. Thus, binding properties of PEI 
with miR were tested using electrophoresis (Figure 10 A). It was shown, that miR polyplexes 
composed of an NP ratio greater than 0.5 completely retarded miR migration in the gel. 
Therefore, we concluded that at our optimized NP ratio 10, PEI polyplexes efficiently bound 
miR and formed tight complexes which is in line with previous findings  [172, 228]. Thereby, 
miR is protected against enzymatic degradation by nucleases  [238]. Moreover, PEI 
polyplexes provide a tool to avoid activation of the innate immune system by small 
RNAs  [239]. 
Successful miR delivery has to face many challenges, e.g. cell targeting, uptake and 
endosomal release  [178]. It was shown, that the size of nanoparticles can influence cellular 
uptake thus playing an essential role for in vitro and in vivo applications  [240]. In our 
experiments, miR/PEI complexes composed of an NP ratio of 10 had a hydrodynamic 
diameter around 100 nm (Figure 10 C). Although siRNAs are small sized molecules around   
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7 nm length, also in previous studies it was shown that PEI formed complexes between 70 to 
100 nm size which was explained by the complexation of several siRNAs into one 
complex  [157, 228]. Binding of miR/PEI complexes to MNPs further increased particle sizes 
between 150 to 200 nm. However, previous studies have shown that a particle size between 
50 to 200 nm was optimal for efficient uptake via endocytosis  [178, 241]. Thus, both 
miR/PEI and miR/PEI/MNP complexes should be taken up and processed inside the cell in a 
similar way and speed  [242]. Hence, this might be an explanation for comparable uptake 
efficiencies of MNP-containing complexes and PEI polyplexes (Figure 9). 
Moreover, surface charge of transfection complexes was investigated (Figure 10 B). While 
MNPs alone were negatively charged (~ −17 mV), miR/PEI complexes with an NP ratio of 10 
had a positive surface charge (~ +40 mV). Compared to our results, Kwok et al showed 
similar surface charges for siRNA/PEI complexes at an NP ratio of 10  [228]. It can therefore 
be concluded that due to its presence on the surface, PEI formed a protective cover around 
miR to avoid degradation by endonucleases  [238]. Moreover, cell uptake was enhanced by 
positively charged complexes which efficiently bind to negatively charged cell 
membranes  [226]. Furthermore, PEI provides efficient endosomal escape due to the “proton 
sponge effect”  [174, 243]. Magnetic complexes containing 1 μg/ml iron in MNPs showed a 
strong positive surface charge (~ +33 mV) providing optimal stability of transfection 
complexes in suspension by repulsive forces. In contrast, miR/PEI/MNP complexes with 
higher MNP concentrations (2 to 6 μg/ml iron in MNPs) had a surface charge between +8 to 
+15 mV. Previously, it was shown that nanoparticles with a surface charge below +30 mV 
were less stable and tended to build aggregates over time  [244, 245]. Summarizing highest 
uptake rates, lowest cytotoxicity and optimal physicochemical properties, magnetic 
transfection complexes composed of an NP ratio of 10 combined with 5 pmol/cm² miR and    
1 μg/ml iron in MNPs were selected as optimal parameters for all following experiments in 
expanded hMSCs. 
 
4.4 Intracellular Transfection Performance of miR/PEI/MNP Complexes in 
Expanded hMSCs 
 
After the optimization of stable complexes for successful miR delivery into expanded hMSCs, 
we investigated release and processing of pre-miR-335 from our optimized magnetic vector. 
Thereby, miR-335 served as proof-of-concept model which is known to target defined genes 
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(e.g. TNC, RUNX2) that are influencing proliferation, differentiation and migration of 
hMSCs  [144, 246]. In these experiments, pre-miR was chosen due to its higher stability 
compared to mature miR. Moreover, pre-miR contains more nucleotides (~ 70 nucleotides) 
providing higher number of negatively charged phosphate groups in their backbone which are 
required for sufficient PEI complexation compared to less stable mature miR (~ 22 
nucleotides)  [125]. Beside the benefits regarding complex formation, transfected pre-miR has 
to undergo an additional processing step in the cytosol comparable to endogenously expressed 
miRs following the RNAi cascade  [117]. Initially, processing of pre-miR into the mature 
strand was investigated by real-time PCR with respect to different endogenous normalization 
controls (miR-16, miR-191, RNU-6B; Figure 11 A). The accuracy of this method is critically 
dependent on appropriate reference RNA targets for normalization. For an optimal 
normalization, controls should be stably expressed along with the target being independent of 
environmental influences or experimental treatment  [247]. Moreover, they are necessary for 
correct evaluation of quantitative data. In previous studies, miR-16 and RNU-6B were 
frequently used for miR expression normalization  [248, 249, 250]. Moreover, Peltier and 
Latham suggested miR-191 as an optimal normalization target  [251]. Our results 
demonstrated no significant differences of miR-335 levels when RNU-6B, miR-16 or miR-
191 were used for normalization after transfection of expanded hMSCs with miR, miR/PEI or 
miR/PEI/MNP complexes. Thus, we concluded that RNU-6B, miR-16 or miR-191 were all 
suitable normalization controls for miR expression experiments. For the following real-time 
PCR experiments, RNU-6B was selected as standard normalization control. 
Subsequently, we investigated the processing of pre-miR-335 and the kinetics of mature miR-
335 levels 5, 24 and 72 hours after transfection in expanded hMSCs (Figure 11 B). Although 
transfection with mere pre-miR resulted in high uptake rates (Figure 7, 8, 9), 5 hours after 
transfection mature miR-335 level was just slightly increased by 10-fold compared to 
untreated hMSCs. Moreover, miR-335 values were decreased to normal expression levels 
within 72 hours of observation indicating a fast degradation of unprotected miR. Thus, 
transfection using miR alone seemed to be not suitable for in vitro applications. Furthermore, 
transfection performances of miR/PEI and miR/PEI/MNP complexes were investigated. 
Already 5 hours after transfection, miR-335 levels were significantly increased using miR/PEI 
or miR/PEI/MNP complexes when compared to mere miR transfection. After 24 hours, miR-
335 levels were further increased by more than 1,000-fold after transfection with PEI- or 
MNP-containing complexes, respectively, and reached a maximum. In contrast to previous 
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results for DNA delivery, after 24 hours no differences between miR/PEI- and 
miR/PEI/MNP-mediated transfection in expanded hMSCs were observed indicating different 
release kinetics for miR delivery  [220]. Interestingly, after 3 days miR-335 values remained 
at the same level after MNP-based transfection indicating a steady release of miRs. In 
contrast, miR-335 level was decreased by more than 3-fold after transfection using miR/PEI 
complexes when compared to magnetic miR/PEI/MNP complexes. Hence, we concluded a 
better consistent long term effect of MNP-mediated transfection which might be beneficial for 
clinical applications. 
In order to explain the different transfection performances of MNP-containing complexes and 
PEI polyplexes 72 hours after transfection, we intended to visualize transfection complexes 
inside the cell. Therefore, all components of miR/PEI and miR/PEI/MNP complexes were 
selectively labeled with different fluorochromes. Recently, our group developed a labeling 
technique for DNA-based transfection complexes. Although the selected fluorochromes had 
close emission and excitation spectra, it was shown that no interactions between the dyes 
occurred. Moreover, it was demonstrated, that 3-color labeling of DNA/PEI/MNP complexes 
slightly enhanced particle size (~ 200 nm). However, it did not affect transfection efficiency 
and cell viability. Therefore, it was concluded that microscopic observations could be 
correlated to transfection data  [220]. Hence, we adopted this labeling protocol for 
miR/PEI/MNP complexes. Initially, magnetic polyplexes were visualized in the absence of 
cells (Figure 12). Thus, we could investigate quality of labeling as well as shape of 
complexes. Labeled magnetic polyplexes showed rounded complexes with a good signal-to-
noise ratio of all components. Moreover, miR was visually co-localized with PEI together 
with MNPs. Thus, modification of magnetic complexes by fluorescent labeling was not 
influencing complex formation. Subsequently, we applied labeled complexes in expanded 
hMSCs and investigated the performance of miR/PEI and miR/PEI/MNP complexes 72 hours 
after transfection (Figure 13). After transfection with PEI polyplexes, miR was found inside 
the nucleus still condensed by PEI. In line with our results, previous studies have shown 
comparable results after transfection with PEI using DNA or siRNA, respectively  [220, 228, 
252]. However, miR-mediated RNAi requires cytoplasmatic release. Therefore, mature miR 
levels might be decreased 72 hours after transfection as processing of delivered pre-miR is 
hindered due to the wrong cellular localization of transfection complexes (Figure 11). In 
contrast, in our experiments MNP-based complexes were randomly distributed entirely in the 
cytoplasm but not in the nucleus. For DNA transfection using magnetic polyplexes, similar 
 4 Discussion 73 
 
 
 
effects were observed. It was stated that due to the strong biotin-streptavidin binding between 
MNPs and PEI resulting in bigger particle size when compared to PEI polyplexes, magnetic 
complexes cannot enter the nucleus. Consequently, DNA has to be released in the cytosol 
following nuclear entry  [202, 203]. Therefore, MNP-based transfection may provide benefits 
particularly for miR delivery as miR exert their function in the cytosol. Consequently, the 
different transfection mechanisms of miR/PEI and miR/PEI/MNP complexes might be an 
explanation for the better long term effect of MNP-containing complexes. 
After testing release and processing of mature miR-335 from transfection complexes, we 
investigated functionality by knockdown of target genes 5, 24 and 72 hours after transfection 
(Figure 14). Previous studies revealed TNC and RUNX2 as target genes of miR-335  [144, 
246]. It was shown, that the extracellular matrix protein TNC is involved in the regulation of 
proliferation and migration in cancer cells  [253, 254]. Moreover, RUNX2 is a transcription 
factor and regulating osteogenic differentiation  [144, 255]. In our experiments, transfection 
with mere miR did not significantly down-regulate TNC and RUNX2 compared to control 
within 72 hours after transfection. In agreement with our result, previously it was shown that 
unprotected siRNA was not able to perform efficient gene knockdown due to the lower 
stability and faster degradation when compared to PEI polyplexes  [157, 172, 229]. However, 
after 24 hours, transfection with miR/PEI or miR/PEI/MNP complexes resulted in a 
significant knockdown of TNC and RUNX2 mRNA levels, respectively, when compared to 
untreated cells. Corresponding to our miR-335 processing data (Figure 11), 72 hour after 
miR/PEI transfection, the expression level of RUNX2 started to increase again which might 
be a reason of PEI-mediated nuclear delivery of transfection complexes into the wrong 
compartment as shown in Figure 13. Moreover, it might indicate the beginning of a depletion 
of delivered miR and a temporal limited effect of these complexes. Interestingly, after MNP-
mediated transfection target genes expression was further decreased by 50% to 60% and was 
significantly down-regulated as compared to miR/PEI transfection. This effect might be a 
consequence of a constant release of miR from MNP-containing complexes into the cytosol 
for efficient RNAi within 72 hours as shown in our previous results (Figure 11, 13). 
Moreover, it underlines our hypothesis of a sustained effect by MNPs. 
In addition, we investigated the influence of TNC knockdown by miR-335 on cell migration 
after transfection using magnetic complexes (Figure 15). In this experiment a wound healing 
assay was started 24 hours after transfection to observe the time frame in which TNC 
expression was maximally reduced by 40% to 60% (Figure 14). Our results showed no 
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difference after miR/PEI/MNP transfection containing not functional scrambled miR 
compared to untransfected control. Therefore, we could exclude an influence on cell motility 
by MNP-based complexes. Interestingly, after transfection with magnetic polyplexes using 
miR-335, cell migration was significantly decreased as shown by a minor overgrown surface 
area compared to untransfected cells. In line with our results, Tavazoie et al showed a 
significant reduction by 30% of cell migration in two cancer cell lines after retroviral-
mediated transduction of miR-335  [246]. Moreover, Tomé et al could demonstrate similar 
results in expanded hMSCs  [144]. Conclusively, we developed stable magnetic, non-viral 
transfection complexes for effective miR delivery and release following significant gene 
silencing of target genes in expanded hMSCs. 
 
4.5 Optimization of MNP-Mediated Transfection in Freshly Isolated hMSCs 
 
To avoid the risks related to cell expansion (e.g. contaminations, altered gene expression, loss 
of stem cell markers and differentiation capacity), we adopted our optimized non-viral 
approach for transfection of freshly isolated hMSCs, thus making it more relevant for clinical 
applications. As uncultured hMSCs showed a different cell morphology and a slightly altered 
immunophenotype (Figure 4, 6) we started to optimize miR amounts (ranging between 2.5 to 
15 pmol/cm² miR) of transfection complexes (Figure 16) taking advantage of previous 
experiments using expanded cells (Figure 7). In contrast to transfection in cultivated hMSCs, 
transfection complexes composed of 2.5 pmol/cm² miR were not taken up by freshly isolated 
cells. However, after transfection with polyplexes using 5 pmol/cm² miR uptake rates were 
significantly enhanced compared to mere miR transfection. In line with our previous results 
(Figure 7), an increase in miR amounts (10 to 15 pmol/cm² miR) did not lead to a further 
enhancement of uptake rates after polyplex-mediated transfection. Moreover, cytotoxicity of 
the different complex formulations was investigated. Therefore, untreated cells were used as 
control representing about 20% cytotoxicity which was caused by the isolation process. 
Increasing miR amounts showed a dose-dependent enhancement of cytotoxicity when 
compared to control. Similar to our results in expanded hMSCs, after transfection with 
polyplexes composed of 15 pmol/cm² miR highest cytotoxicity values (about 80%) were 
reached in freshly isolated cells. Although transfection experiments in freshly isolated hMSCs 
showed mostly comparable trends to cultured cells, absolute values of uptake rates (Δ 20%) 
and cytotoxicity (Δ 55%) were different. It was shown by others, that suspension cells 
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comparable to our freshly isolated hMSCs are more difficult to transfect than adherent cells 
similar to our cultivated cells  [256, 257]. Therefore, altered cell size and morphology which 
was previously shown (Figure 4) might influence the transfection performance. Moreover, the 
different surface marker expression (Figure 6) might lead to changes on the cell membrane 
which could affect uptake of transfection complexes. To further improve the uptake efficiency 
of polyplexes, we selected two miR amounts (5 and 10 pmol/cm² miR) with moderate uptake 
rates but still no cytotoxic effect when compared to untreated cells for the following 
experiments. According to PEI-based transfection in expanded hMSCs, the selected miR 
amounts were combined with previously tested NP ratios (NP ratio 2.5, NP ratio 5, NP ratio 
10) and transferred to efficient miR delivery into freshly isolated CD105
+
 cells (Figure 17). In 
accordance with our previous results in cultured cells (Figure 9), we could show that PEI-
based complexes composed of an NP ratio of 10 combined with 5 pmol/cm² miR yielded 
highest uptake rates (56%) in uncultivated hMSCs. In contrast to miR transfection in 
expanded hMSCs, polyplexes with a higher NP ratio (NP ratio 33) were not taken up by fresh 
hMSCs and resulted in enhanced cytotoxicity. Thus, freshly isolated hMSCs might react more 
sensitive to potentially detrimental agents. Interestingly, the uptake efficiency could be further 
enhanced in non-cultured cells (69%) by using polyplexes composed of a lower NP ratio (NP 
ratio 2.5) and combined with a higher miR amount (10 pmol/cm² miR). Additionally, the 
strategy of reducing the NP ratio decreased cytotoxicity to values comparable to the control 
group due to the lower amount of PEI used. Thus, PEI polyplexes consisting of an NP ratio of 
2.5 combined with 10 pmol/cm² miR were investigated in further experiments and compared 
to miR/PEI complexes previously optimized for expanded cells (NP ratio 10, 5 pmol/cm² 
miR). 
Targeted gene delivery is an essential requirement for clinical applications. Previously, it was 
shown that MNP-based gene delivery enables both in vivo targeting of transfection complexes 
towards the desired area and guiding of magnetically modified cells using an externally 
applied magnetic field  [183, 191]. Therefore, the combination of MNPs with the optimal 
miR/PEI complex formulations (NP ratio 2.5, 10 pmol/cm² miR vs NP ratio 10, 5 pmol/cm² 
miR) might be a promising strategy to increase selectivity and efficiency in freshly isolated 
hMSCs (Figure 18). Regarding previous results in expanded cells (Figure 9), miR/PEI 
complexes were coupled to 1 or 2 μg/ml iron in MNPs, respectively. Similar to MNP-
mediated transfection in expanded hMSCs, uptake efficiencies of different magnetic complex 
formulations did not significantly differ when compared to polyplex transfection in freshly 
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isolated cells. Moreover, absolute values were comparable to those obtained in cultured 
hMSCs (~ 75%). Additionally, magnetic complexes had no cytotoxic effect in fresh hMSCs 
when compared to controls indicating that the investigated MNP concentrations were well 
tolerated by the cells. Therefore, with respect to previous characterization of MNP-containing 
complexes (Figure 10), magnetic polyplexes composed of 1 µg/ml iron in MNPs were 
considered for the following experiments. Furthermore, in this experiment we applied a 
magnetic field for magnetofection and examined the impact on miR delivery into freshly 
isolated hMSCs (Figure 18). Interestingly, after 5 hours, magnetic forces did not lead to an 
enhanced miR transfection. Moreover, no significant differences in uptake efficiency and 
cytotoxicity in the presence or absence of a magnetic field were observed. In line with our 
results, Huth et al showed that the application of a magnetic field did not alter uptake 
mechanisms or processing of transfection complexes inside the cell  [193]. Moreover, it was 
demonstrated in vitro that the enhanced transfection efficiency of MNP-based complexes was 
only caused by an accelerated sedimentation of complexes on the cell membrane facilitated by 
an external magnet  [192, 193]. However, Plank et al showed that the enhanced efficiencies of 
magnetically assisted transfection were observed just for a short time. 4 hours after 
transfection, efficiencies of magnetic complexes under the exposure of a magnetic field were 
comparable to those without the application of a magnet  [258]. 
After optimization of the magnetic vectors for efficient miR delivery into freshly isolated 
hMSCs, we investigated release and processing of transfected miR-335 (Figure 19) as it was 
previously done in expanded cells. It was shown that both tested miR/PEI/MNP complexes 
were capable of efficiently deliver and release miR-335 inside fresh hMSCs shown by 70-fold 
to 220-fold enhancement of miR-335 expression levels. Although similar uptake efficiencies 
of MNP-based transfection in freshly isolated and expanded hMSCs were reached, miR-335 
levels were about 10-times lower in freshly isolated cells when compared to cultured hMSCs. 
This could be a reason of different cell morphologies as shown in Figure 4. In contrast to 
freshly isolated hMSCs, expanded cells were big cells with a large cell surface capable of 
taking up relatively more transfection complexes within one cell (Figure 13). Therefore, the 
amount of released miR might be enhanced in cultivated cells compared to fresh hMSCs. 
Interestingly, magnetic polyplexes consisting of an NP ratio of 2.5 combined with                 
10 pmol/cm² miR, which were shown to be less stable  [228], showed 3-fold higher miR-335 
levels when compared to MNP-containing complexes optimized for transfection in cultured 
hMSCs (NP ratio 10, 5 pmol/cm² miR). It seemed that the lower stability of magnetic 
 4 Discussion 77 
 
 
 
polyplexes composed of an NP ratio of 2.5 may allow a faster release of miR inside the 
cytosol promoting higher miR-335 levels. Moreover, due to the smaller size of freshly 
isolated hMSCs, the transport distance of transfection complexes to reach the perinuclear 
region for RNAi is shorter when compared to expanded cells. Hence, transfection complexes 
composed of a lower NP ratio (NP ratio 2.5) might be beneficial in fresh hMSCs. 
 
4.6 Comparison of Different Magnetic miR Carrier Systems in Freshly Isolated 
hMSCs 
 
Additionally, miR delivery of our selected miR/PEI/MNP vectors were compared to 
commercially available magnetic transfection reagents in freshly isolated hMSCs (Figure 20). 
As standard transfection reagents commonly used for magnetofection, we combined miR with 
Magnetofectamine
®
. Being a combination of Lipofectamine
®
 2000 and CombiMag particles, 
Magnetofectamine
®
 was successfully applied in various cell types for the delivery of different 
nucleic acids (e.g. DNA, siRNA) using an external magnetic field  [194, 195, 196, 199]. 
Besides the combination with cationic lipids, it is proposed that CombiMag particles can be 
further combined with cationic polymers (e.g. PEI). Although these magnetic transfection 
reagents were widely applied in a broad range of indications, none of them were used for miR 
delivery before. In our experiments, both miR/PEI/MNP vectors showed highest uptake rates 
which were comparable to those reached with miR/PEI/CombiMag complexes. Underlining 
our results, Huth et al showed that magnetic vector assembly is essentially influencing 
transfection efficiency. Both, miR/PEI/MNP and miR/PEI/CombiMag complexes were 
prepared in a similar manner. At first, miR was complexed by PEI providing its positive 
surface charge (Figure 10) followed by coupling to MNPs or CombiMag particles, 
respectively. Thus, it is likely that both magnetic polyplexes were equally taken up and 
processed inside the cell, resulting in comparable miR uptake rates. Moreover, we compared 
our optimized polyplex-based miR/PEI/MNP complexes to lipoplex-mediated 
Magnetofectamine
®
. Cationic lipids were suggested as the most efficient chemical 
transfection reagents in suspension cells  [259]. However, our magnetic polyplexes reached 
similar values. Although polyplexes and lipoplexes show different chemical structures, 
interactions with nucleic acids and intracellular transfection mechanisms, previously it was 
proposed that they might have similar uptake mechanisms via endocytosis  [260, 261]. 
Furthermore, polyplex- and lipoplex-mediated transfection seems to underlie comparable 
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kinetics thus leading to equal miR uptake efficiencies. Furthermore, no cytotoxic effects of 
the different magnetic transfection complexes were observed when compared to control 
indicating that the investigated magnetic transfection reagents were well tolerated in freshly 
isolated hMSCs. Therefore, the investigated magnetic vectors may provide direct genetic 
modifications of damaged tissue by introducing therapeutic miRs in vivo  [183]. Furthermore, 
in vitro magnetic modifications of stem cells before transplantation may allow specific 
guiding or retention of transplanted cells by an externally applied magnetic field  [191]. 
 
4.7 In Vitro Targeting of Magnetically Modified hMSCs 
 
In 2013, Lang et al investigated engraftment of intramyocardially transplanted stem cell 
derivatives for treatment of heart infarction. It was shown, that only 5% of the transplanted 
cells retained at the site of injection due to massive washout of the beating heart  [262]. Thus, 
magnetic targeting of transplanted cells may provide a strategy to increase the cell 
engraftment and therapeutic outcome of stem cells after myocardial infarction. Recently, 
Vandergriff et al labeled human cardiosphere derived stem cells with paramagnetic iron oxide 
nanoparticles and investigated magnetic targeting of magnetically modified cells in the 
infarcted heart. After intracoronary injection, labeled cells were visibly targeted towards the 
magnet and accumulated around the ischemic zone. In contrast, without magnetic targeting 
the majority of stem cells were washed out directly after injection. Conclusively, they could 
demonstrate that magnetic targeting of labeled cardiac stem cells facilitated cell retention and 
engraftment thus improving cardiac regeneration  [263]. Besides the ability of targeted 
delivery of magnetically modified stem cells towards the side of interest, the combination of 
magnetic targeting with simultaneous gene delivery by using the same vector might further 
enhance therapeutic benefits. Previously, we have shown efficient miR delivery in both 
freshly isolated and expanded hMSCs after transfection with our optimized miR/PEI/MNP 
vector (Figure 9, 18). Furthermore, we investigated magnetic targeting of transfected cells in 
vitro. Initially, paramagnetic properties of MNPs were tested (Figure 21). According to the 
definition of paramagnetic nanoparticles  [240], our MNPs exhibited magnetization only in 
the presence of a magnetic field. Without the application of a magnet, MNPs stopped their 
targeted movements and remained a stable colloidal suspension. Furthermore, magnetic 
targeting of freshly isolated and expanded hMSCs was investigated after transfection with our 
optimized magnetic complexes (Figure 22). We could demonstrate specific targeting of 
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hMSCs after MNP-mediated transfection shown by accumulation of cells in the area of the 
magnetic field. However, hMSCs grew homogenously distributed when no magnet was 
applied which is in agreement with our previous results (Figure 21). Therefore, our non-viral 
magnetic vector allows specific control of stem cell properties by efficient miR delivery 
combined with precise magnetic targeting of transfected cells in vivo. Thus, it might provide a 
basis for innovative therapies to regenerate the injured heart. 
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5 Conclusion 
 
In conclusion, we successfully developed a novel non-viral magnetic miR delivery vector for 
both efficient modification of freshly isolated hMSCs using miR/PEI/MNP complexes and 
specific targeting of transfected hMSCs by an external magnetic field in vitro. Initially, we 
established a standardized protocol for optimal miR/PEI/MNP complex formation in 
expanded hMSCs with respect to their physicochemical properties as well as highest uptake 
rates and lowest cytotoxicity. Moreover, our MNP-containing complexes provided efficient 
release and processing as well as prolonged functionality of delivered miR in cultured hMSCs 
compared to polyplex transfection, which might be beneficial for successful stem cell-based 
gene therapy. Furthermore, we successfully transferred our non-viral approach for efficient 
miR delivery to freshly isolated CD105
+
 hMSCs with uptake rates equaling those of miR 
transfection in expanded cells. Compared to commercially available magnetic transfection 
reagents, transfection performance of our MNP-containing complexes yielded similar values. 
Therefore, we were the first to approve these magnetic transfection reagents for efficient miR 
delivery in freshly isolated hMSCs. Additionally, both freshly isolated and expanded hMSCs 
could be specifically targeted by an externally applied magnetic field after transfection with 
the corresponding miR/PEI/MNP complexes, facilitating retention and engraftment of 
transplanted cells in vivo. Finally, this thesis provides the basis for efficient miR delivery into 
freshly isolated hMSCs using our novel magnetic carriers. In the future, further pre-clinical 
tests have to be performed to investigate magnetic targeting of modified hMSCs under in vivo 
conditions. Pharmacokinetics and pharmacodynamics of magnetically modified cells as well 
as of excreted transfection complexes have to be investigated before applying it to humans. In 
addition, in vitro, our MNP-containing complexes can be further applied for 
magselectofection, being a combination of magnetically activated cell isolation and 
simultaneous transfection. Subsequently, this approach could be further transferred to fully 
automated and closed magnetic cell separation systems (e.g. CliniMACS Prodigy
®
 from 
Miltenyi Biotec) to provide safe and standardized cell products which are in line with current 
good manufacturing practices guidelines. Thus, autologous freshly isolated and transfected 
cells could be immediately transplanted during the same surgery. Therefore, we expect that 
our magnetic non-viral carrier will serve as a solid basis for innovative strategies in heart 
regeneration. 
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List of Abbreviations 
 
°C degree Celsius 
µ micro (10
-6
) 
Δ difference 
AF 488 Alexa Fluor 488 
Akt serine/threonine-specific protein kinase 
AmCyan Anemonia majano cyan fluorescent protein 
APC allophycocyanin 
Bax Bcl-2-associated X protein 
Bcl-2 B-cell lymphoma-2 
BGBl Bundesgesetzblatt 
BMP bone morphogenetic protein 
BSA bovine serum albumin 
CCR2 C-C chemokine receptor type 2 
CCR3 C-C chemokine receptor type 3 
CCR4 C-C chemokine receptor type 4 
CD cluster of differentiation 
cDNA copy DNA 
cm
2
 square centimeter 
CO2 carbon dioxide 
CT threshold cycle 
CVDs cardiovascular diseases 
CXCR4 C-X-C chemokine receptor type 4 
Cy3 cyanine 3 
Cy5 cyanine 5 
Da Dalton 
DAPI 4',6-diamidino-2-phenylindole 
dH2O distilled water 
DLS dynamic light scattering 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
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DOPE dioleoyl phosphatidylethanolamine 
DOSPA 
2,3-dioleoyloxy-N-[2-(spermine-carboxamido)ethyl]-N,N-
dimethyl-1-propanaminium trifluoroacetate 
dsRNA double stranded RNAs 
e.g. for example 
EDTA ethylenediaminetetraacetic acid 
Egr-1 early growth response protein-1 
eNOS endothelial nitric oxide synthase 
ESchG Embryonenschutzgesetz 
FABP-4 fatty acid binding protein-4 
FBS fetal bovine serum 
FGF-2 fibroblast growth factor-2 
Flk-1 fetal liver kinase-1 
g gram 
g standard gravity 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
HER-2 human epidermal growth factor receptor-2 
hESCs human embryonic stem cells 
HGF hepatocyte growth factor 
HIF-1α hypoxia-inducible factor-1α 
HLA human leukocyte antigen 
HMG-CoA 3-hydroxy-3-methylglutaryl-coenzyme A 
hMSCs human mesenchymal stem cells 
hMSZ humane mesenchymale Stammzellen 
HO-1 heme oxygenase-1 
Hsp-20 heat shock protein-20 
IGF-1 insulin-like growth factor-1 
IgG immunoglobulin G 
IL interleukin 
iPSCs induced pluripotent stem cells 
k kilo 
Klf4 Kruppel-like factor 4 
l liter 
lncRNA long non-coding RNA 
LSM laser scanning microscopy 
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m milli (10
-3
) 
M molar 
MACS magnetic activated cell sorting 
MCGS mesenchymal cell growth supplement 
MEF myocyte enhancer factor 
miR microRNA 
miR-Cy5 microRNA labeled with cyanine 5 
MNCs mononuclear cells 
MNP magnetic nanoparticles 
MNP-565 magnetic nanoparticles labeled with Atto 565 
Mol mole 
MRI magnetic resonance imaging 
mRNA messenger RNA 
MSCBM Mesenchymal Stem Cell Basal Medium 
MSCGM™ Mesenchymal Stem Cell Growth Medium 
MSCs mesenchymal stem cells 
n amount of substance 
n nano (10
-9
) 
n statistical sample size 
N nitrogen 
NaCl sodium chloride 
ncRNA non-coding RNA 
Nkx2.5 NK2 homeobox 5 
NP ratio molar ratio of PEI nitrogen and miR phosphate 
n.s. no significant difference 
Oct3/4 octamer-binding transcription factor-3/4 
P phosphate 
PALS phase analysis light scattering 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PE phycoerythrin 
PEI polyethylenimine 
PEI-488 polyethylenimine labeled with Alexa Fluor 488 
PerCP peridinin-chlorophyll proteins 
PFA paraformaldehyde 
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pH negative logarithm of the hydrogen ion concentration 
PUMA p53 upregulated modulator of apoptosis 
R relative expression ratio 
RISC RNA-induced silencing complex 
RNA ribonucleic acid 
RNAi RNA interference 
RT reverse transcription 
RUNX2 runt-related transcription factor 2 
SD standard deviation 
SDF-1 stromal-derived factor-1 
SEM standard error of the mean 
SIM structured illumination microscopy 
siRNA small interfering RNA 
Sox2 SRY-related high-mobility-group-box protein 2 
T tesla 
TBE TRIS-borate-EDTA buffer 
TGF transforming growth factor 
TNC tenascin C 
TRIS 2-amino-2-hydroxymethyl-propane-1,3-diol 
TβRI type I transforming growth factor-beta receptor 
TβRII type II transforming growth factor-beta receptor 
TβRIII type III transforming growth factor-beta receptor 
U unit 
V volt 
V volume 
VEGF vascular endothelial growth factor 
vs versus 
w/w weight to weight ratio 
WHO World Health Organization 
α-MEM minimum essential medium alpha 
 
  
 7 Appendix v 
 
 
 
List of Figures 
 
Figure 1:  Biogenesis and Function of miR and siRNA .................................................... 11 
Figure 2:  Ex Vivo Genetic Modifications of hMSCs using miRs. .................................... 13 
Figure 3:  Construction of Magnetic Transfection Complexes. ........................................ 18 
Figure 4:  Cell Morphology of Freshly Isolated and Expanded hMSCs ........................... 39 
Figure 5:  Differentiation Capacity of hMSCs .................................................................. 40 
Figure 6:  Immunophenotyping of hMSCs ........................................................................ 43 
Figure 7:  Transfection Optimization of miR Amounts in Cultured hMSCs .................... 44 
Figure 8:  Transfection Optimization of PEI Amounts in Cultured hMSCs ..................... 45 
Figure 9:  Transfection Optimization of MNP Amounts in Cultured hMSCs .................. 46 
Figure 10:  Classification of Transfection Complexes ........................................................ 48 
Figure 11:  Monitoring of pre-miR-335 Processing in Cultured hMSCs ............................ 50 
Figure 12:  Visualization of Transfection Complexes ......................................................... 51 
Figure 13:  Intracellular Visualization of Transfection Complexes in Cultured hMSCs .... 52 
Figure 14:  Gene Knockdown of TNC and RUNX2 after miR-335 Transfection in Cultured 
hMSCs............................................................................................................... 53 
Figure 15:  Inhibition of the Migratory Ability of Cultured hMSCs after miR-335 
Transfection ...................................................................................................... 54 
Figure 16:  Transfection Optimization of miR Amounts in Freshly Isolated hMSCs ......... 56 
Figure 17:  Transfection Optimization of PEI Amounts in Freshly Isolated hMSCs ......... 58 
Figure 18:  Transfection Optimization of MNP Amounts in Freshly Isolated hMSCs with 
and without the Application of a Magnetic Field ............................................. 59 
Figure 19:  Processing of pre-miR-335 in Freshly Isolated hMSCs ................................... 60 
Figure 20:  Transfection Performances of Optimized miR/PEI/MNP Complexes in 
Comparison with Commercially Available Magnetic Transfection Carriers in 
Freshly Isolated hMSCs .................................................................................... 62 
Figure 21:  Paramagnetic Properties of MNPs .................................................................... 63 
Figure 22:  In Vitro Magnetic Targeting of Cultured hMSCs ............................................. 64 
 
  
 7 Appendix vi 
 
 
 
List of Tables 
 
Table 1:  List of Chemicals Used in this Thesis............................................................... 20 
Table 2:  List of Solutions Used in this Thesis ................................................................ 22 
Table 3:  Immunofluorescent Labeling of hMSCs ........................................................... 25 
Table 4:  Transfection Protocol for Cultured hMSCs ...................................................... 28 
Table 5:  Transfection Protocol for Freshly Isolated hMSCs .......................................... 28 
Table 6:  Preparation of RT Master Mix for RT of miRs ................................................ 34 
Table 7:  Program for RT of miRs ................................................................................... 34 
Table 8:  Real-Time PCR Pipetting Scheme for miR Quantification .............................. 35 
Table 9:  Program for Real-Time PCR ............................................................................ 35 
Table 10:  Preparation of 2x RT Master Mix for RT of Target Genes .............................. 36 
Table 11:  Program for RT of Target Genes ...................................................................... 36 
Table 12:  Real-Time PCR Pipetting Scheme for Target Gene Quantification ................. 37 
 
List of Equations 
 
Equation 1:  Calculation of the NP Ratio Referring to the Number of Nitrogen Atoms (N) in 
PEI per Phosphate Group (P) of miR ................................................................ 27 
Equation 2:  Calculation of the Relative Expression Ratio (R) using the ΔΔCT Method ..... 35 
 
  
 7 Appendix vii 
 
 
 
Curriculum Vitae 
 
PERSÖNLICHE DATEN 
 
Name Anna Schade 
(geb. Sponholz) 
 
Anschrift Glockengießerhof 5 
18055 Rostock 
  
Geburtsdatum 17.02.1987 
  
Geburtsort Rostock 
  
Staatsangehörigkeit deutsch 
  
Familienstand verheiratet, 2 Kinder (2008, 2014) 
 
SPRACHEN 
 
Deutsch Muttersprache 
Englisch fließend in Wort und Schrift 
 
BERUFLICHER WERDEGANG 
 
Schulausbildung 
 
06/2005 CJD Jugenddorf-Christophorusschule Rostock  
Abschluss: Abitur 
Leistungskurse: Mathematik, Biologie, Chemie 
 
Universitäre Ausbildung 
 
10/2005 – 07/2009 Universität Rostock, Medizinische Fakultät 
Studium: Medizinische Biotechnologie 
Abschluss: Bachelor of Science 
Thema der Bachelorarbeit: „Influence of Tetradecylthioacetic 
Acid for the Deposition of Amyloid in an Alzheimer`s 
Disease Mouse Model“, am NRL in Rostock 
 
10/2009 – 09/2011 Universität Rostock, Medizinische Fakultät 
Studium: Medizinische Biotechnologie 
Abschluss: Master of Science 
Thema der Masterarbeit: „Intracellular Visualization of 
Nanoparticle-based Gene Delivery via Selective Fluorescent 
Labeling”, am FKGO in Rostock 
 
 7 Appendix viii 
 
 
 
Berufliche Erfahrungen 
 
10/2008 -12/2009 Neurodegeneration Research Laboratory (NRL), 
Universitätsmedizin Rostock 
Anstellung: studentische Hilfskraft 
 
06/2009 – 09/2011 Forschungslabor für kardialen Gewebe- und Organersatz 
(FKGO)/ Klinik für Herzchirurgie, Universitätsmedizin 
Rostock 
Anstellung: studentische Hilfskraft 
 
10/2011 – laufend Forschungslabor für kardialen Gewebe- und Organersatz 
(FKGO)/ Klinik für Herzchirurgie, Universitätsmedizin 
Rostock 
Beginn der Arbeiten zur Erlangung des Doktorgrades  
Thema: “MicroRNA-based Stem Cell Modifications using 
Magnetic Transfection Complexes - A Non-Viral Approach 
towards Cardiac Regeneration." 
Anstellung: wissenschaftliche Mitarbeiterin 
  
10/2011 - laufend Mitglied im strukturierten Promotionsstudiengang 
„Molekulare Mechanismen Regenerativer Prozesse“ & 
Mitglied in der Graduiertenakademie Rostock 
 
KONFERENZEN 
 
12/2012 3rd EACTS Meeting on Cardiac and Pulmonary 
Regeneration, Berlin/ Deutschland,  
„An innovative non-viral strategy for efficient microRNA 
delivery in human mesenchymal stem cells for regenerative 
medicine“, Posterpräsentation 
 
06/2013 Rostock’s Eleven 2013, Rostock/ Deutschland,  
„Neuartiger Genträger für die Modifikation von 
Stammzellen”, Vortrag 
 
03/2014 BioNanoMed 2014, 5th International Conference of 
Nanotechnology, Medicine & Biology, Krems/ Österreich, 
„Nonviral gene carriers for efficient modifications of human 
mesenchymal stem cells for cardiac regeneration“, Vortrag  
 
  
 7 Appendix ix 
 
 
 
PUBLIKATIONEN 
 
Schade, A.; Müller, P.; Delyagina, E. et al. Magnetic Nanoparticle Based Nonviral 
MicroRNA Delivery into Freshly Isolated CD105+ hMSCs. Stem Cells Int., 1-11 (2014). 
 
Schade, A.; Delyagina, E.; Scharfenberg, D. et al. Innovative strategy for microRNA delivery 
in human mesenchymal stem cells via magnetic nanoparticles. IJMS 14 (6), 10710–10726 
(2013). 
 
Delyagina, E.; Schade, A.; Scharfenberg, D. et al. Improved transfection in human 
mesenchymal stem cells: Effective intracellular release of pDNA by magnetic polyplexes. 
Nanomedicine (Lond) 0(0), 1-18 (2013). 
 
Delyagina, E., Li, W., Schade, A. et al. Low Molecular Weight Polyethyleimine conjugated 
to magnetic nanoparticles as a vector for gene delivery. AIP Conference Proceedings, 
CP1311, 479-484 (2010). 
 
BETREUUNG 
 
08/2012 “Magnetic nanoparticle-based delivery of microRNA-335 into 
human mesenchymal stem cells”,  
Masterarbeit Dorothee Scharfenberg (Medizinische 
Biotechnologie), Note: 1,0 
  
08/2013 “Comparative analysis of different non-viral miR transfection 
methods in primary hMSCs“,  
Masterarbeit Paula Müller (Biologie), Note: 1,0 
 
  
 7 Appendix x 
 
 
 
Acknowledgement 
 
First of all, I would like to thank my principal supervisor Prof. Gustav Steinhoff for giving me 
the opportunity to work on this interesting topic. Thanks for inspiring scientific discussions, 
motivation and support which have been majorly influencing my last four years. 
I would like to express my gratitude to Prof. Robert David for his kind supervision and 
evaluation of my work as well as critical revision of my dissertation. His continuous support 
essentially contributed to the successful completion. 
I am grateful for the persistent critical evaluation of my results by Prof. Michael Glocker and 
the members of the structured PhD program “Molecular Mechanisms of Regenerative 
Processes”. 
Special thanks are directed to my colleague and friend Evgenya Delyagina for her outstanding 
support, her good advice, fruitful discussions, joy and the good times spent together. Her 
devotion to science has always impressed and motivated me. 
I sincerely thank Anna Skorska and Madeleine Bartsch for their practical support, friendly 
advice and optimism. 
Additionally, I want to extend my thanks to the whole FKGO research group: Dr. Ralf Gäbel, 
Dr. Christian Rimmbach, Dr. Cajetan Lang, Dr. Nan Ma, Dr. Wenzhong Li, Dr. Weiwei 
Wang, Dr. Yue Zhang, Natalia Voronina, Frauke Hausburg, Paula Müller, Julia Jung, Marion 
Ludwig, Peter Mark, Erik Pittermann, Dorothee Scharfenberg, Margit Schwarz, Anita Tölk, 
Margit Fritsche. Thank you for a pleasant working atmosphere, profound discussions and a 
great time. 
Moreover, I would like to express my gratitude to the team of the Reference and Translation 
Center for Cardiac Stem Cell Therapy: Dr. Gudrun Tiedemann, Dr. Ulrike Ruch, Dr. Jana 
Große, Dr. Sandra Kurzawski, Dr. Frauke Stähler, Jana Gabriel and Katrin Höfer. Thanks for 
helpful advice and suggestions. 
I give warm thanks to my husband and my daughters, Nico, Greta and Klara, for their 
everlasting love, their support, patience and motivation. 
I am also very grateful to my family, especially my parents, Dr. Marion and Dr. Frank 
Sponholz, for their love, moral support and encouraging words during the past years. 
Finally, I would like to thank my friends for their patience and ongoing help during this 
exciting time. 
  
 7 Appendix xi 
 
 
 
Selbständigkeitserklärung 
 
Ich versichere, die vorliegende Arbeit zum Thema „ MicroRNA-based Stem Cell 
Modifications using Magnetic Transfection Complexes - A Non-Viral Approach towards 
Cardiac Regeneration“ selbstständig verfasst und keine anderen Hilfsmittel als die 
angegebenen benutzt zu haben. Stellen, die anderen Werken dem Wortlaut oder dem Sinn 
nach entnommen sind, habe ich in jedem einzelnen Fall durch Angabe der Quelle kenntlich 
gemacht. 
 
Ich erkläre, meine wissenschaftliche Arbeit nach den Prinzipien der guten wissenschaftlichen 
Praxis gemäß der gültigen „Satzung der Universität Rostock zur Sicherung guter 
wissenschaftlicher Praxis“ angefertigt zu haben. 
 
 
Rostock, 18. Juni 2015 
 
 
 
 
 
 
